Original Article
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
N Engl J Med 1998; 339:1665-1671December 3, 1998
- Abstract
Background
Antithrombotic drugs are used after coronary-artery stenting to prevent stent thrombosis. We compared the efficacy and safety of three antithrombotic-drug regimens — aspirin alone, aspirin and warfarin, and aspirin and ticlopidine — after coronary stenting.
Methods
Of 1965 patients who underwent coronary stenting at 50 centers, 1653 (84.1 percent) met angiographic criteria for successful placement of the stent and were randomly assigned to one of three regimens: aspirin alone (557 patients), aspirin and warfarin (550 patients), or aspirin and ticlopidine (546 patients). All clinical events reflecting stent thrombosis were included in the prespecified primary end point: death, revascularization of the target lesion, angiographically evident thrombosis, or myocardial infarction within 30 days.
Results
The primary end point was observed in 38 patients: 20 (3.6 percent) assigned to receive aspirin alone, 15 (2.7 percent) assigned to receive aspirin and warfarin, and 3 (0.5 percent) assigned to receive aspirin and ticlopidine (P=0.001 for the comparison of all three groups). Hemorrhagic complications occurred in 10 patients (1.8 percent) who received aspirin alone, 34 (6.2 percent) who received aspirin and warfarin, and 30 (5.5 percent) who received aspirin and ticlopidine (P<0.001 for the comparison of all three groups); the incidence of vascular surgical complications was 0.4 percent (2 patients), 2.0 percent (11 patients), and 2.0 percent (11 patients), respectively (P=0.02). There were no significant differences in the incidence of neutropenia or thrombocytopenia (overall incidence, 0.3 percent) among the three treatment groups.
Conclusions
As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone. After coronary stenting, aspirin and ticlopidine should be considered for the prevention of the serious complication of stent thrombosis.
Media in This Article
Figure 1
Cumulative Incidence of the Primary End Point in the Three Treatment Groups.Table 1
Base-Line Characteristics of the Patients.Article Activity
- Article
The implantation of coronary stents has become a major form of revascularization therapy for coronary artery disease. In early clinical trials,1 there were high rates of stent thrombosis (approaching 20 percent), leading to the adoption of an antiplatelet and anticoagulant regimen that included intravenous low-molecular-weight dextran, oral aspirin and dipyridamole, and intravenous heparin followed by oral warfarin. The incorporation of this aggressive antithrombotic treatment strategy in subsequent randomized clinical trials2-4 reduced the risk of acute and subacute stent thrombosis to approximately 3.5 percent. However, as compared with conventional balloon angioplasty, stenting with aggressive antithrombotic-drug therapy doubled the length of hospitalization (from three to six days) and increased the rate of hemorrhagic and vascular complications from 3 to 4 percent to 7 to 13 percent.2,3,5
More recently, registry data have demonstrated that the risk of stent thrombosis can be further reduced by the use of a combination of high-pressure, balloon-expandable stents and antithrombotic therapy with aspirin and ticlopidine.6-8 A single-center, randomized trial also demonstrated the superiority of aspirin and ticlopidine over aspirin and warfarin for the prevention of stent thrombosis in high-risk patients.9 Moreover, a single-center registry and one small, randomized trial suggested that aspirin alone might be adequate for the prevention of stent thrombosis.10,11 There has also been concern about the possibility of neutropenia and thrombocytopenia in association with ticlopidine therapy.12 We compared the 30-day clinical outcomes for three antithrombotic-drug regimens — aspirin alone, aspirin and warfarin, and aspirin and ticlopidine — after elective coronary-artery stenting.
Methods
Objectives and Design of the Study and Selection of Patients
The primary objective was to compare the incidence of stent thrombosis in patients with single-vessel or multivessel disease of native coronary arteries who were successfully treated with a high-pressure, balloon-expandable stent at 1 of 50 centers in the United States and who were then randomly assigned to receive one of three antithrombotic-drug regimens. The implantation of a Palmaz–Schatz stent (Cordis, Warren, N.J.) was considered to be successful if the final degree of stenosis within the stent was less than 10 percent (by visual estimate), there was no evidence of thrombus or of dissections (more than grade B according to the National Heart, Lung, and Blood Institute criteria), there was grade 3 flow according to the criteria of the Thrombolysis in Myocardial Infarction study, and no more than two stents were needed to treat one long (≤25 mm) lesion or two focal (≤12 mm) lesions in one or two native coronary arteries. Patients who did not meet the criteria for successful stenting were enrolled in a prospective trial that was identical to the randomized trial in terms of data collection and follow-up except that patients were not assigned to a specific drug-treatment strategy.
Randomization was not blinded, but all end points were adjudicated by a clinical events committee whose members were unaware of the patients' treatment assignments. The study complied with the Declaration of Helsinki regarding investigations in humans and was approved for an investigational-device exemption by the Food and Drug Administration (FDA), and all investigational sites received approval from their local hospital investigational review boards. All patients gave written informed consent.
Patients were eligible for enrollment if they had one or two target lesions with more than 60 percent stenosis in a 3-to-4-mm native coronary artery, not involving the left main coronary artery or a major coronary bifurcation. Other exclusion criteria were the presence of additional stenoses within the target vessel; recent (within 7 days before enrollment) acute myocardial infarction; known contraindications to the use of aspirin, ticlopidine, or warfarin; a history of bleeding diathesis; current treatment with abciximab; and planned angioplasty of another lesion within 30 days after enrollment.
Eligible patients were randomly assigned in equal proportions with use of a prespecified randomization sequence to one of the three antithrombotic-drug regimens, according to clinical site and history of diabetes mellitus.
Coronary-Stent Procedure
All patients received nongeneric, non–enteric-coated aspirin (325 mg) and intravenous heparin (10,000 to 15,000 U) to maintain an activated clotting time of 250 to 300 seconds during the implantation of the stents. Before the stents were implanted, lesions were treated with balloon angioplasty, directional atherectomy, or rotational atherectomy. The stent was implanted with a stent delivery system (Johnson and Johnson, Warren, N.J.) approved by the FDA that consisted of a specially designed balloon catheter onto which a standard 15-mm Palmaz–Schatz coronary stent had been crimped within a protective nylon sheath. The sizing of the stents followed standard FDA guidelines: the ratio of the diameter of the balloon to the diameter of the artery was 1.1 to 1.0, with a deployment pressure of 6 to 8 atmospheres. The technique used in this study was designed to achieve a residual stenosis of less than 10 percent by visual estimate, which usually required further dilation of the balloon at high pressure (≥16 atmospheres) with a separate high-pressure balloon measuring 15 to 20 mm. To reduce the number of variables that might influence stent thrombosis, all procedures were performed with use of the same low osmolar ionic angiographic contrast medium (ioxaglate meglumine, Mallinckrodt, St. Louis).
Antithrombotic-Drug Regimens
The three regimens were as follows: 325 mg of non–enteric-coated aspirin (Bayer, West Haven, Conn.) orally per day; 325 mg of non–enteric-coated aspirin per day and intravenous heparin (initial dose, 10,000 to 15,000 U per day), with the dose titrated to achieve an activated partial-thromboplastin time of 40 to 60 seconds and discontinued once an international normalized ratio of 2.0 to 2.5 was reached with the use of oral warfarin; and 325 mg of non–enteric-coated aspirin per day and 250 mg of ticlopidine (Ticlid, Sanofi, New York) orally twice a day. No further heparin was given after the procedure except among patients assigned to receive warfarin. The duration of ticlopidine and warfarin treatment was four weeks. Treatment assignments were not masked, and the first dose of ticlopidine or warfarin was administered at the conclusion of the stenting procedure.
Data Collection and Analysis of End Points
Detailed case-report forms were completed by the clinical coordinator at each site, monitored by independent study monitors, and submitted to the data-coordinating center (Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston). Angiograms obtained during the stenting procedure were submitted to the angiographic core laboratory (Washington Hospital Center, Washington, D.C.), where they were analyzed with a computer-based system (Medis, Leiden, the Netherlands). The patients were assessed at discharge and four weeks after the stenting procedure for the occurrence of adverse clinical events. All events were classified by an independent clinical events committee whose members were unaware of the patients' treatment assignments.
The prespecified 30-day primary end point, which reflected the occurrence of stent thrombosis, was a hierarchical composite of death from any cause, revascularization of the target lesion without death, evidence of thrombosis of the target vessel on repeated angiography without revascularization, or nonfatal myocardial infarction in patients who did not undergo repeated angiography. Secondary end points included the achievement of less than 50 percent residual stenosis without death or emergency bypass surgery (defined as procedure success), procedure-related myocardial infarction, hematologic dyscrasias (neutropenia or thrombocytopenia), hemorrhagic complications, and vascular surgical complications. Myocardial infarctions (procedure-related and within 30 days after the procedure) were defined by a new Q wave that lasted at least 0.04 second in two or more contiguous leads or a creatine kinase concentration that was more than two times the upper limit of normal in the presence of an elevated concentration of MB isoenzyme. A major bleeding complication was defined as any procedure-related bleeding episode that required transfusion. Vascular surgical complications included any retroperitoneal hematoma, a vascular-access hematoma of more than 4 cm, and a pseudoaneurysm or arteriovenous fistula requiring surgery or ultrasonographic compression. Hematologic status was evaluated on the basis of a minimum of two complete blood counts performed two and four weeks after the stenting procedure; neutropenia was defined as a reduction in the absolute white-cell count to less than 1200 per cubic millimeter, and thrombocytopenia as a reduction in the platelet count to below 80,000 per cubic millimeter.
Statistical Analysis
The trial was designed to determine whether the regimen of aspirin and ticlopidine was as effective as the regimen of aspirin and warfarin in preventing stent thrombosis (the null hypothesis) and whether there were any significant differences in the primary end point between the regimen of aspirin and ticlopidine and the regimen of either aspirin and warfarin or aspirin alone. The prespecified plan therefore called for a sequential-analysis strategy. The null hypothesis was established with use of Blackwelder's formula,13 and two comparisons of difference in the primary end point were then made. Adjustments for multiple comparisons were made to maintain an overall type I error rate of 0.05 and are reflected in the reported P values. There was no prespecified interim analysis for early termination of the study, but the data and safety monitoring committee reviewed early safety data after the enrollment of each 250 patients.
For the null hypothesis, we assumed that the rate of stent thrombosis was 4 percent in the group assigned to aspirin and warfarin, with an increase of 3 percent or more in this value taken as an indication of the inferiority of this treatment. A total of 528 patients were required in each group for the study to have the power to detect such a difference, with a type I error of 0.05 and a type II error of 0.2. For the two conditional tests of difference, the same 4 percent rate of stent thrombosis was assumed for the group assigned to aspirin and warfarin and the aspirin-only group. For the study to have the ability to detect a 30-day stent-thrombosis rate of 1.1 percent or less in the group assigned to ticlopidine and aspirin with a statistical power of 80 percent and a one-sided alpha error of 0.025, 527 patients were required for each group. The trial was therefore designed to enroll 550 patients per group, for a total of 1650 patients.
All comparisons were based on the intention-to-treat principle. Continuous variables were compared with the use of analysis of variance for comparisons among all three groups, and binary variables were compared with the use of the chi-square test (or Fisher's exact test in the case of any variable that included fewer than five events) and were presented with nominal two-tailed P values. Relative risks of selected primary and secondary end points were also calculated (with confidence intervals) for the prespecified pairwise comparison. Differences in the median time to a primary event were analyzed with the Kruskal–Wallis nonparametric rank-sum test for multiple groups. A stepwise multivariable logistic model of the primary end point was used to evaluate base-line predictors and the treatment effect simultaneously. All statistical analyses were performed with SAS computer software (version 6.12, SAS Institute, Cary, N.C.).14
Results
Enrollment of Patients and Base-Line Characteristics
A total of 1965 patients with 2147 lesions were enrolled between February 1996 and November 1996. Of these, 1653 patients (84.1 percent) with 1772 lesions met the criteria for successful stent placement and were enrolled in the randomized trial. The remaining 312 patients with 375 lesions were enrolled in a parallel registry. Overall, 99.3 percent met the secondary end point of procedure success (less than 50 percent residual stenosis without death or emergency bypass surgery), including all 1653 patients who underwent randomization and 298 of the 312 patients (95.5 percent) entered in the parallel registry. This report focuses on the results of the randomized patients, of whom 1534 had a single lesion treated and 119 had two lesions treated. A total of 557 patients were assigned to receive aspirin alone, 550 patients were assigned to receive aspirin and warfarin, and 546 patients were assigned to receive aspirin and ticlopidine. The base-line characteristics of the patients were similar in the three groups (Table 1Table 1
Base-Line Characteristics of the Patients. and Table 2Table 2
Angiographic and Procedural Characteristics.). Before placement of the stent, balloon angioplasty alone was performed in 88.1 percent, rotational atherectomy in 6.2 percent, and directional atherectomy in 0.6 percent, with no pretreatment in 5.1 percent.Primary End Point
The overall incidence of the combined primary end point was 2.3 percent, and the overall incidence of death within 30 days was 0.06 percent. The primary and secondary end points in the individual groups are summarized in Table 3Table 3
Primary and Secondary Events in the First 30 Days after Stenting., and the relative risks of selected end points are given in Table 4Table 4
Relative Risk of Primary and Secondary Events in the Group Assigned to Aspirin and Ticlopidine as Compared with the Group Assigned to Aspirin Alone and the Group Assigned to Aspirin and Warfarin.. The primary end point occurred in a total of 38 patients, 20 (3.6 percent) assigned to aspirin only, 15 (2.7 percent) assigned to aspirin and warfarin, and 3 (0.5 percent) assigned to aspirin and ticlopidine (P=0.001 for the comparison of all three groups). The relative risk of the primary end point in the group assigned to aspirin and ticlopidine was 0.15, as compared with the risk in the group assigned to aspirin alone (P<0.001), and 0.20, as compared with the risk in the group assigned to aspirin and warfarin (P=0.01) (Table 4).Three components of the primary end point were mainly responsible for the differences among the three groups and were highly correlated: revascularization of the target lesion (P=0.002), angiographically evident thrombosis (P=0.005), and recurrent myocardial infarction (P=0.01). There were also significant differences in the incidence of revascularization of the target lesion and angiographically evident thrombosis between the group assigned to aspirin and ticlopidine and either the group assigned to aspirin only or the group assigned to aspirin and warfarin (Table 4). Among the entire randomized cohort, there was only one death, in the aspirin-alone group.
The cumulative incidence of primary events is shown in Figure 1Figure 1
Cumulative Incidence of the Primary End Point in the Three Treatment Groups., with a mean time to a primary event of 0.7 day for the group assigned to aspirin and ticlopidine, 2.9 days for the group assigned to aspirin and warfarin, and 3.7 days for the group assigned to aspirin alone (P=0.17 for the difference among the three groups). A stepwise logistic model of the primary end point was evaluated for the following potential predictors: age, sex, presence of diabetes mellitus, number of lesions treated (two vs. one), length of the lesion, dissection grade, appearance of angiographically evident thrombus, and post-treatment minimal diameter of the lumen after adjustment for the type of antithrombotic-drug regimen. The primary end point was positively associated with a dissection grade of B or greater (odds ratio, 3.82; P=0.002) and a smaller post-treatment minimal luminal diameter (odds ratio, 5.00 for each additional 1-mm decrease; P<0.001).Among the 312 patients who did not undergo randomization, the incidence of the combined primary end point was 3.5 percent. Multivariable analysis indicated that the number of stents implanted was positively associated with stent thrombosis (P=0.01) and the use of aspirin and ticlopidine was negatively associated with stent thrombosis (P=0.08).
Secondary End Points
There were no significant differences in the incidence of procedure-related myocardial infarctions among the three groups (overall incidence, 3.8 percent) (Table 3). There were three cerebrovascular accidents (overall incidence, 0.2 percent) and five cases of severe neutropenia or thrombocytopenia (overall incidence, 0.3 percent). The incidence of hemorrhagic complications and vascular surgical complications was significantly different among the three groups (P<0.001 and P=0.02, respectively) (Table 3). The group assigned to aspirin and ticlopidine had a relative risk of hemorrhagic complications of 3.06 (P=0.002) and a relative risk of vascular surgical complications of 5.61 (P=0.02) as compared with the group assigned to aspirin alone. The risk of these events in the group assigned to aspirin and ticlopidine was similar to that in the group assigned to aspirin and warfarin.
Discussion
This randomized trial compared the ability of three antithrombotic-drug regimens to prevent stent thrombosis. The chief finding was that a combination of aspirin and ticlopidine was superior to either a combination of warfarin and aspirin or aspirin alone in the prevention of stent thrombosis after successful stenting. The risk of stent thrombosis with aspirin and warfarin was slightly lower than with aspirin alone.
Our study differs from earlier trials in that randomization required high stent-implantation pressures and the achievement of a predefined optimal result. Our finding of an intermediate (2.7 percent) risk of stent thrombosis among patients assigned to receive aspirin and warfarin, between that of the patients assigned to receive aspirin and ticlopidine (0.5 percent) and that of the patients assigned to receive aspirin alone (3.6 percent), is in contradistinction to earlier data from a single-center randomized trial conducted in Germany, which suggested that warfarin may promote stent thrombosis.9 Several factors may explain this difference: the intensity of anticoagulation was lower in our study (target international normalized ratio, 2.0 to 2.5), the sample population in the German study included many patients with acute myocardial infarction (24 percent), and our patients had to have a successful angiographic result before they underwent randomization. The modified regimen of aspirin and warfarin that was used in our study was at least as effective as aspirin alone in preventing stent thrombosis, with no added risk of stent thrombosis. The high rate of stent thrombosis in the group assigned to aspirin alone is an important finding and contradicts the results of a recent registry study and of a small, randomized trial, which reported that the rate of stent thrombosis was similar in the group assigned to aspirin and ticlopidine and the group treated with aspirin alone.11,12
Our study has several important secondary findings. The overall death rate was 0.06 percent, and only 1 of 38 patients (2.6 percent) who reached the primary end point died. This rate is markedly lower than the rate of death from stent thrombosis in previous trials (range, 11 to 24 percent1-3,9,15,16) and may reflect differences in selection factors used or improved diagnosis and treatment strategies for stent thrombosis. The fact that Q-wave myocardial infarction occurred in 45 percent of those who reached the primary end point in our study is evidence that the clinical consequences of stent thrombosis remain severe.
The significantly lower incidence of stent thrombosis during treatment with aspirin and ticlopidine as compared with treatment with aspirin alone was offset by a slight but significantly increased risk of hemorrhagic and vascular surgical complications. Despite the widespread belief that combination therapy with aspirin and ticlopidine is associated with a lower rate of vascular surgical complications than therapy with aspirin and warfarin, there was no significant difference in these end points between the two groups. Interestingly, the incidence of hemorrhagic complications in the group assigned to aspirin and warfarin was lower in our study than in previous trials,2,3 suggesting that femoral-artery puncture and sheath-removal techniques have improved over the years.
There was also no significant difference in the risk of neutropenia or thrombocytopenia between the group assigned to aspirin and ticlopidine (0.5 percent) and either the group assigned to aspirin alone (0.2 percent) or the group assigned to aspirin and warfarin (0.2 percent). These values are similar to the 0.8 percent incidence of severe neutropenia more than two months after the start of treatment reported for patients who receive long-term ticlopidine therapy to prevent strokes.10 An incidence of reversible ticlopidine-induced neutropenia of 0.8 percent was also reported in the French Multicenter Registry of 2900 patients.16 Although these data may be taken as evidence that it is safe to use ticlopidine for up to 4 weeks, stent thrombosis generally occurs within the first 14 days after the stenting procedure and may occur even earlier (a mean of 0.7 day in our study) in patients who are given aspirin and ticlopidine. Although not directly evaluated in this study, the early time to thrombosis indirectly suggests that the course of ticlopidine may be shortened to two weeks, which may further reduce the risk of neutropenia and thrombocytopenia. Importantly, despite the absence of severe hematologic dyscrasias in our study, there are continued reports of thrombotic thrombocytopenic purpura in association with ticlopidine therapy (incidence, approximately 1 in 1600 patients), including short-term treatment after coronary stenting.17,18 The vast majority of these hematologic disturbances occur after two weeks of ticlopidine treatment,18 thereby lending further support to the suggestion to shorten the duration of ticlopidine therapy after stenting to two weeks.
In summary, we demonstrated the efficacy and safety of a combination of ticlopidine and aspirin as a means of preventing stent thrombosis in patients with ischemic coronary syndromes. The superiority of this antithrombotic regimen over aspirin alone and a combination of aspirin and warfarin supports its use as the primary therapy after coronary stenting.
Supported by a grant from Cordis, a Johnson and Johnson Company, Warren, N.J.
Source Information
From Washington Hospital Center, Washington, D.C. (M.B.L., J.J.P.); Beth Israel Deaconess Medical Center, Boston (D.S.B., D.E.C., K.K.L.H., R.E.K.); Miriam Hospital, Providence, R.I. (P.C.G.); St. Joseph's Hospital, Syracuse, N.Y. (A.G.); Georgetown Medical Center, Washington, D.C. (D.J.D.); Allegheny General Hospital, Pittsburgh (D.M.L.); Rhode Island Hospital, Providence (D.O.W.); and London School of Hygiene and Tropical Medicine, London (S.J.P.).
Address reprint requests to Dr. Leon at Cardiovascular Research and Education, Cardiology Research Foundation at the Washington Hospital Center, 110 Irving St. NW, Suite 4B-1, Washington, DC 20010.
Other members of the Stent Anticoagulation Restenosis Study are listed in the Appendix.
Appendix
The following principal investigators and study coordinators also participated in the Stent Anticoagulation Restenosis Study: University of Texas Health Science Center–Brooke Army Medical Center, San Antonio: S. Bailey, G. Cooper-Reade; Beth Israel Deaconess Medical Center, Boston: P. Rooney; Scripps Memorial Hospital, La Jolla, Calif.: M. Buchbinder, D. Koester; Lancaster Heart Foundation, Lancaster, Pa.: P. Casale, J. Tuzi; Yale University Hospital, New Haven, Conn.: M. Cleman, J. Davey; Northwestern University Medical School, Chicago: C. Davidson, J. Espisito; Baylor University Medical Center, Dallas: S. DeMaio, I. Joukova; Temple University, Philadelphia: E. Deutsch, B. Flynn; Georgetown University, Washington, D.C.: J. Gannuscio; Cleveland Clinic Foundation, Cleveland: S. Ellis, L. Korcuska; Texas Heart Institute, Houston: D. Fish, M. Harlan; Aurora Denver Cardiology, Aurora, Colo.: S. Friedrich, K. Bickett; Mid-West Cardiology Research Foundation, Columbus, Ohio: B. George, D. Smith; St. Joseph's Hospital, Syracuse, N.Y.: S. Wagner; Miriam Hospital, Providence, R.I.: N. Wright; Arizona Heart Institute, Phoenix: R. Heuser, S. Spooner; University of Pennsylvania, Philadelphia: J. Hirshfeld, L. Felderstein; Mayo Clinic, Rochester, Minn.: D. Holmes, L. Pierre; Christ Hospital, Cincinnati: D. Kereiakes, B. Gervers, L. Martin; Atlanta Cardiology, Atlanta: W. Knopf, N. Yarbriough; Washington Hospital Center, Washington, D.C.: K. Donovan; Hartford Hospital, Hartford, Conn.: R. McKay, D. Hall; University of Chicago, Chicago: T. Feldman, C. Kienlen; Lenox Hill Hospital, New York: J. Moses, N. Cohen; Stanford University Hospital, Stanford, Calif.: S. Oesterle, N. Jenkins; Cardiology Associates of Lubbock, Lubbock, Tex.: P. Overlie, D. Stone; Massachusetts General Hospital, Boston: I. Palacios, K. Martin; Mount Sinai Hospital, New York: S. Sharma, D. Ratner; University of Florida, Gainesville: C. Pepine, E. Franco; Ochsner Clinic, New Orleans: S. Ramee, N. McCarthy; Scottsdale Cardiovascular Center, Scottsdale, Ariz.: D. Rizik, C. Wojciechowski; Monroe Regional Medical Center, Ocala, Fla.: R. Feldman, B. Merchant; William Beaumont Hospital, Royal Oaks, Mich.: R. Safian, M. Safian, D. Davey; Oklahoma Foundation for Cardiovascular Research, Oklahoma City: D. Schmidt, M. Johnson; Maimonides Medical Center, Brooklyn, N.Y.: J. Shani, N. Schulhoff; Washington Adventist Hospital, Takoma Park, Md.: F. Shawl, S. Cornell; St. Luke's Medical Center, Kansas City, Mo.: T. Shimshack, P. Rosson; Sanger Clinic, Charlotte, N.C.: C. Simonton, G. Schwarz; University of Texas Medical School, Houston: R. Smalling, C. Underwood; Allegheny General Hospital, Pittsburgh: R. Saputski; Chattanooga Heart Institute, Chattanooga, Tenn.: A. Stratienko, V. Marion; Scripps Clinic and Research Foundation, La Jolla, Calif.: P. Teirstein, K. Stevens; Medical College of Virginia, Richmond: G. Vetrovec, R. O'Brian; Sharp Memorial Hospital, San Diego, Calif.: M. Buchbinder, J. Fenner; Rhode Island Hospital, Providence: J. Muratori, E. Donaghey; Duke University Medical Center, Durham, N.C.: J. Zidar, S. Sawchak; Washington University School of Medicine, St. Louis: J. Lasala, K. Meyers. Coordinating Center and Biostatistical Core Laboratory: M. Fitzpatrick, C. Senerchia, A. Dejardin (Boston); Quantitative Angiographic Core Laboratory: A. Merrit, A. Lansky (Washington, D.C.); Data Safety and Monitoring Committee: T. Ryan (chair), J. Orav (statistician), B. Gersh, S. Smith, D. Faxon; Clinical Events Committee: J. Marcus, J. Carrozza, W. Manning, D. Cohen, J. Kannam, L. Epstein (Boston); Electrocardiographic Core Laboratory: A. Goldberger (Boston).
- References
References
1
Serruys PW ,Strauss BH ,Beatt KJ , et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;321:13-17
Full Text | Web of Science2
Fischman DL ,Leon MB ,Baim DS , et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501
Full Text | Web of Science | Medline3
Serruys PW ,de Jaegere P ,Kiemeneij F , et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495
Full Text | Web of Science | Medline4
Macaya C ,Serruys PW ,Ruygrok P , et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial: Benestent Study Group. J Am Coll Cardiol 1996;27:255-261
CrossRef | Web of Science | Medline5
Cohen DJ ,Krumholz HM ,Sukin CA , et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial: Stent Restenosis Study Investigators. Circulation 1995;92:2480-2487
Web of Science | Medline6
Colombo A ,Hall P ,Nakamura S , et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688
Web of Science | Medline7
Serruys PW ,Emanuelsson H ,van der Giessen W , et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II Pilot Study. Circulation 1996;93:412-422
Web of Science | Medline8
Baim DS ,Carrozza JP Jr . Stent thrombosis: closing in on the best preventive treatment. Circulation 1997;95:1098-1100
Web of Science | Medline9
Schomig A ,Neumann F-J ,Kastrati A , et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089
Full Text | Web of Science | Medline10
Hass WK ,Easton JD ,Adams HP Jr , et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507
Full Text | Web of Science | Medline11
Albiero R ,Hall P ,Itoh A , et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation: comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95:1145-1156
Web of Science | Medline12
Hall P ,Nakamura S ,Maiello L , et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222
Web of Science | Medline13
Blackwelder WC . “Proving the null hypothesis“ in clinical trials. Control Clin Trials 1982;3:345-353
CrossRef | Medline14
The logistic procedure. In: SAS/STAT user's guide, version 6. Vol. 2. Cary, N.C.: SAS Institute, 1990:1071-134.
15
Morice MC ,Zemour G ,Benveniste E , et al. Intracoronary stenting without Coumadin: one month results of French multicenter study. Cathet Cardiovasc Diagn 1995;35:1-7
CrossRef | Medline16
Karrillon GJ ,Morice MC ,Benveniste E , et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-1527
Web of Science | Medline17
Bennett CL ,Weinberg PD ,Rozenberg-Ben-Dror K ,Yarnold RR ,Kwaan HC ,Green D . Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-544
Web of Science | Medline18
Bennett CL ,Kiss JE ,Weinberg PD , et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998;352:1036-1037
CrossRef | Web of Science | Medline
- Citing Articles (474)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. The Journal of Thoracic and Cardiovascular Surgery 143:1, 4-34
CrossRef3
Julio F. Marchini, Andre Manica, Kevin Croce. (2011) Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine
CrossRef4
Karin Mauer, Jorge F. Saucedo. 2011. Cardiology-In-Depth Look: Advances in Antiplatelet Therapy. .
CrossRef5
Marco Valgimigli. (2011) Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention. Current Opinion in Cardiology 26, S1-S3
CrossRef6
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Jennifer Yu, Helen Parise, Ke Xu, Stuart J. Pocock, Gregg W. Stone. (2011) Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). The American Journal of Cardiology
CrossRef7
Giuseppe Sangiorgi, Marie-Claude Morice, Ezio Bramucci, Marco Ferlini, Liliana Grinfeld, Anna Petronio, Carlo Pierli, Alessandro Iadanza, Giuseppe Biondi-Zoccai, Antonio Colombo. (2011) Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial. EuroIntervention 7:7, 813-819
CrossRef8
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology
CrossRef9
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology
CrossRef10
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Journal of the American College of Cardiology
CrossRef11
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology
CrossRef12
Shoichiro Daimon, Hidenobu Terai. (2011) Influence of Antiplatelet Medications on Bleeding Events in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 15:5, 454-459
CrossRef13
Takahiro Mito, Shin-ichiro Miura, Kohei Takada, Rie Koyoshi, Joji Morii, Makoto Sugihara, Ken Mori, Atsushi Iwata, Hideto Sako, Hiroaki Nishikawa, Akira Kawamura, Keijiro Saku. (2011) A case of coronary artery disease with antiphospholipid syndrome that showed repeated stent thrombosis. Journal of Cardiology Cases 4:2, e80-e86
CrossRef14
Azeem Latib, Alfonso Ielasi, Luca Ferri, Alaide Chieffo, Cosmo Godino, Mauro Carlino, Matteo Montorfano, Antonio Colombo. (2011) Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology
CrossRef15
G. Lemesle, C. Delhaye. (2011) La thrombose de stent, de plus en plus rare !. Annales de Cardiologie et d'Angéiologie
CrossRef16
Dániel Aradi, András Komócsi. (2011) Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?. Platelets1-10
CrossRef17
J. Dorler, M. Edlinger, H. F. Alber, J. Altenberger, W. Benzer, G. Grimm, K. Huber, O. Pachinger, H. Schuchlenz, P. Siostrzonek, G. Zenker, F. Weidinger, , J. Altenberger, M. Pichler, W. Benzer, G. Bonner, F. Weidinger, T. Brunner, G. Gaul, F. Gratze, G. Zenker, M. Juhasz, H. Silberbauer, K. Kerschner, F. Leisch, H. Krappinger, H. Wimmer, K. Laubreiter, G. Grimm, P. Siostrzonek, H. Mayr, T. Neunteufl, G. Maurer, G. Norman, H. Weber, O. Pachinger, J. Dorler, H. F. Alber, F. X. Roithinger, G. Unger, K. Huber, H. Wallner, W. Weihs, H. Schuchlenz. (2011) Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. European Heart Journal
CrossRef18
Arun Kalyanasundaram, A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, 592-600
CrossRef19
Angel Lanas, Ping Wu, Jennie Medin, Edward J. Mills. (2011) Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis. Clinical Gastroenterology and Hepatology 9:9, 762-768.e6
CrossRef20
Gianluca Campo, Matteo Miccoli, Matteo Tebaldi, Jlenia Marchesini, Luca Fileti, Monia Monti, Marco Valgimigli, Roberto Ferrari. (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:6, 399-407
CrossRef21
Xiao-dong Wang, Dai-fu Zhang, Xue-bo Liu, Yan Lai, Wei-gang Qi, Yu Luo, Bo Hu, Yi-an Yao. (2011) Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. European Journal of Internal Medicine
CrossRef22
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati, Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, 999-1014
CrossRef23
Nicholas Willis, Rajesh Sachdeva, Barry F. Uretsky. (2011) Bare-metal stent thrombosis after noncardiac surgery greater than 10 years after stent implantation. Catheterization and Cardiovascular Interventions 78:2, 234-236
CrossRef24
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao. (2011) The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation 1:8, 1155-1165
CrossRef25
Gregory Y. H. Lip. (2011) The role of aspirin for stroke prevention in atrial fibrillation. Nature Reviews Cardiology 8:10, 602-606
CrossRef26
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef27
Makoto Sonobe, Toshihiko Sato, Fengshi Chen, Takuji Fujinaga, Tsuyoshi Shoji, Hiroaki Sakai, Ryo Miyahara, Toru Bando, Chen-Long Huang, Hiroshi Date. (2011) Management of patients with coronary stents in elective thoracic surgery. General Thoracic and Cardiovascular Surgery 59:7, 477-482
CrossRef28
Hisao Ogawa, Seiji Hokimoto, Koichi Kaikita, Koichiro Yamamoto, Tadasuke Chitose, Takamichi Ono, Kenichi Tsujita. (2011) Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. Journal of Cardiology 58:1, 6-17
CrossRef29
Brendan Bell, Jamie Layland, Karl Poon, Christian Spaulding, Darren Walters. (2011) Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents. Heart, Lung and Circulation 20:7, 438-445
CrossRef30
Antonio Gutierrez, Sunil V. Rao. (2011) Atrial Fibrillation and Percutaneous Coronary Intervention: Stroke, Thrombosis, and Bleeding. Current Treatment Options in Cardiovascular Medicine 13:3, 203-214
CrossRef31
Qing-Kui Guo, Zhi-Qian Lu, Jin-Ye Wang, Tao Li. (2011) In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. Journal of Materials Science: Materials in Medicine 22:6, 1615-1623
CrossRef32
Man-Hong Jim, Arthur Sze-yue Yung, Gloria Kai-yan Tang, Katherine Yu-yan Fan, Wing-Hing Chow. (2011) Successful use of endothelial progenitor cell capture stents in a coronary artery disease patient with aspirin hypersensitivity who failed initial aspirin desensitization. International Journal of Cardiology 148:3, 350-351
CrossRef33
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef34
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef35
Ajay J. Kirtane, Adriano Caixeta, Philippe Généreux, Rikesh Patel, Jeffrey W. Moses. 2011. Sirolimus and Paclitaxel Eluting Stent Clinical Studies. , 502-518.
CrossRef36
Antonios Polydorou, P. Megaloikonomos, Ad. Polydorou, V. Polydorou, Isabelle Henry, Michel Henry, T. Skandalakis. 2011. Periprocedural Management for Carotid Intervention. , 118-124.
CrossRef37
Hua-Qiao Tan, Ming-Hua Li, Pei-Lei Zhang, Yong-Dong Li, Jian-Bo Wang, Yue-Qi Zhu, Wu Wang. (2011) Reconstructive endovascular treatment of intracranial aneurysms with the Willis covered stent: medium-term clinical and angiographic follow-up. Journal of Neurosurgery 114:4, 1014-1020
CrossRef38
Jonas Persson, Johan Lindbäck, Claes Hofman-Bang, Bo Lagerqvist, Ulf Stenestrand, Ann Samnegard. (2011) Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. EuroIntervention 6:9, 1046-1052
CrossRef39
Gilles Lemesle, Rebecca Torguson, Laurent Bonello, Axel de Labriolle, Gabriel Maluenda, Itsik Ben-Dor, Sara Collins, Asmir Syed, Zhenyi Xue, Lowell Satler, Augusto Pichard, Ron Waksman. (2011) Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. EuroIntervention 6:9, 1053-1059
CrossRef40
Shannon Scholl, Evan S Dellon, Nicholas J Shaheen. (2011) Treatment of GERD and Proton Pump Inhibitor Use in the Elderly: Practical Approaches and Frequently Asked Questions. The American Journal of Gastroenterology 106:3, 386-392
CrossRef41
Baojin Zhu, Zhenxiang Zhao, Patrick McCollam, Johnna Anderson, Jay P. Bae, Haoda Fu, Marjie Zettler, LeRoy LeNarz. (2011) Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Current Medical Research and Opinion 27:3, 633-641
CrossRef42
Nikolaus Sarafoff, Lydia Neumann, Tanja Morath, Isabell Bernlochner, Julinda Mehilli, Albert Schömig, Adnan Kastrati, Dirk Sibbing. (2011) Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. American Heart Journal 161:3, 605-610
CrossRef43
Dániel Aradi, Orsolya Rideg, András Komócsi. (2011) Platelet function monitoring in patients on clopidogrel. Interventional Medicine and Applied Science 3:1, 32-38
CrossRef44
M. Cattaneo. (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:7, 2102-2112
CrossRef45
A Maeda, H Ando, T Asai, H Ishiguro, N Umemoto, M Ohta, M Morishima, A Sumida, T Kobayashi, K Hosohata, K Ushijima, A Fujimura. (2011) Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical Pharmacology & Therapeutics 89:2, 229-233
CrossRef46
Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra L. Close, Amy G. Leishman, David Erlinge. (2011) TRITON and Beyond: New Insights into the Profile of Prasugrel. Cardiovascular Therapeuticsno-no
CrossRef47
Juzar Lokhandwala, Patricia J. M. Best, Yvette Henry, Peter B. Berger. (2011) Allergic Reactions to Clopidogrel and Cross-Reactivity to Other Agents. Current Allergy and Asthma Reports 11:1, 52-57
CrossRef48
Matthew W. Sherwood, Tracy Y. Wang, Richard C. Becker. (2011) How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. Current Treatment Options in Cardiovascular Medicine 13:1, 46-56
CrossRef49
Maurizio Ferrario, Eloisa Arbustini, Margherita Massa, Vittorio Rosti, Nicola Marziliano, Claudia Raineri, Rita Campanelli, Alessandra Bertoletti, Gaetano Maria De Ferrari, Catherine Klersy, Luigi Angoli, Ezio Bramucci, Barbara Marinoni, Marco Ferlini, Enza Moretti, Arturo Raisaro, Alessandra Repetto, Peter J. Schwartz, Luigi Tavazzi. (2011) High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. International Journal of Cardiology 147:1, 124-131
CrossRef50
M. K. Freynhofer, I. Brozovic, V. Bruno, S. Farhan, B. Vogel, G. Jakl, M. Willheim, W. Hübl, J. Wojta, K. Huber. (2011) Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thrombosis and Haemostasis 106:2, 230-239
CrossRef51
H. Fernando, A. M. Dart, K. Peter, J. A. Shaw. (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thrombosis and Haemostasis 105:6, 933-944
CrossRef52
Isaac Lynch, Daniel A. Emmert, Michael H. Wall. (2011) Perioperative Considerations and Management in Patients with Intravascular Stents. Advances in Anesthesia 29:1, 85-112
CrossRef53
Akimitsu MAEDA, Hitoshi ANDO, Takashi KOBAYASHI, Toru ASAI, Hisaaki ISHIGURO, Norio UMEMOTO, Keiko HOSOHATA, Kentarou USHIJIMA, Akio FUJIMURA. (2011) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:3, 151-152
CrossRef54
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef55
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes, D. L. Bhatt, D. J. Moliterno, R. C. Becker, D. J. Angiolillo. (2011) Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis 106:4, 572-584
CrossRef56
John Fani Srour, Gerald W. Smetana. (2011) Triple therapy in hospitalized patients: Facts and controversies. Journal of Hospital Medicinen/a-n/a
CrossRef57
Hirofumi OYAMA, Akira KITO, Hideki MAKI, Kenichi HATTORI, Tomoyuki NODA, Kentaro WADA. (2011) Acute Subdural Hematoma in Patients With Medication Associated With Risk of Hemorrhage. Neurologia medico-chirurgica 51:12, 825-828
CrossRef58
S.W. Werns. (2011) Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Yearbook of Critical Care Medicine 2011, 47-51
CrossRef59
T. Simon. (2010) Pharmacogénétique des antagonistes des récepteurs plaquettaire P2Y12 de l’ADP. Annales de Cardiologie et d'Angéiologie 59, S42-S46
CrossRef60
David Zimrin, Johannes Bonatti, Mark R. Vesely, Eric J. Lehr. (2010) Hybrid Coronary Revascularization: An Overview of Options for Anticoagulation and Platelet Inhibition. The Heart Surgery Forum 13:6, E405-E408
CrossRef61
AHMED ABDEL-LATIF, DAVID J. MOLITERNO. (2010) Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis-When a Rare Disorder Can Predispose to Rare Events. Journal of Interventional Cardiology 23:6, 565-568
CrossRef62
Anne Bellemain-Appaix, David Brieger, Farzin Beygui, Johanne Silvain, Ana Pena, Guillaume Cayla, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot. (2010) New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:19, 1542-1551
CrossRef63
Shamir R Mehta, Jean-Francois Tanguay, John W Eikelboom, Sanjit S Jolly, Campbell D Joyner, Christopher B Granger, David P Faxon, Hans-Jurgen Rupprecht, Andrzej Budaj, Alvaro Avezum, Petr Widimsky, Philippe Gabriel Steg, Jean-Pierre Bassand, Gilles Montalescot, Carlos Macaya, Giuseppe Di Pasquale, Kari Niemela, Andrew E Ajani, Harvey D White, Susan Chrolavicius, Peggy Gao, Keith AA Fox, Salim Yusuf. (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet 376:9748, 1233-1243
CrossRef64
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu Wong. (2010) Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheterization and Cardiovascular Interventions 76:4, 513-524
CrossRef65
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef66
Ameer E. Hassan, Haralabos Zacharatos, Gabriela Vazquez, Gustavo J. Rodriguez, M. Fareed K. Suri, Ramachandra P. Tummala, Robert A. Taylor, Adnan I. Qureshi. (2010) Low Risk of Intracranial and Systemic Hemorrhages in Patients on Dual Antiplatelet Treatment Beyond 1 Month Following Neuroendovascular Angioplasty and/or Stent Placement. Journal of Neuroimagingno-no
CrossRef67
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef68
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Update on the clinical development of cangrelor. Expert Review of Cardiovascular Therapy 8:8, 1069-1077
CrossRef69
David Vivas, Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, 217-226
CrossRef70
Jorge F. Saucedo. (2010) Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30:2, 200-209
CrossRef71
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef72
Cathy Jeon, Susana C. Candia, John C. Wang, Elizabeth M. Holper, Michelle Ammerer, Richard E. Kuntz, Laura Mauri. (2010) Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: A model for protection from acute myocardial infarction. American Heart Journal 160:1, 195-201
CrossRef73
Yee W Wong, Roshan Prakash, Derek P Chew. (2010) Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology 25:4, 305-311
CrossRef74
Kimberly L Campbell, John R Cohn, Michael P Savage. (2010) Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology 3:4, 553-561
CrossRef75
Willibald Hochholzer, Dietmar Trenk, Martin F. Fromm, Christian M. Valina, Christian Stratz, Hans-Peter Bestehorn, Heinz Joachim Büttner, Franz-Josef Neumann. (2010) Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Journal of the American College of Cardiology 55:22, 2427-2434
CrossRef76
G. Y. H. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen, T. Cuisset, P. Kirchhof, F. Marin. (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 31:11, 1311-1318
CrossRef77
Douglass A. Morrison. (2010) Stent Thrombosis. Journal of the American College of Cardiology 55:18, 1943-1944
CrossRef78
, T. Lickfeld, C. Hamm, M. Möckel, J. Vollert, M. Haude. (2010) Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. Der Kardiologe 4:2, 107-123
CrossRef79
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef80
Sonny Dandona, Alexandre F.R. Stewart, Robert Roberts. (2010) Genomics in coronary artery disease: Past, present and future. Canadian Journal of Cardiology 26, 56A-59A
CrossRef81
Scot Garg, Patrick Serruys. (2010) Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy 8:3, 449-470
CrossRef82
O. Ruthmann, A. Seitz, S. Richter, G. Marjanovic, M. Olschewski, U.T. Hopt, A. Fischer, H.-J. Schrag. (2010) Perkutane endoskopische Gastrostomie. Der Chirurg 81:3, 247-254
CrossRef83
Robert B. Schonberger, Ala S. Haddadin. (2010) The Anesthesia Patient with Acute Coronary Syndrome. Anesthesiology Clinics 28:1, 55-66
CrossRef84
Douglass A. Morrison. (2010) Limitations of stints: A good, albeit imperfect, therapy; For a less than perfect world. Catheterization and Cardiovascular Interventions 75:3, 343-344
CrossRef85
Rahul Sakhuja, Laura Mauri. (2010) Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. Annual Review of Medicine 61:1, 215-231
CrossRef86
Ali O. Abualsaud, Mark J. Eisenberg. (2010) Perioperative Management of Patients With Drug-Eluting Stents. JACC: Cardiovascular Interventions 3:2, 131-142
CrossRef87
Dmitriy N. Feldman, Foluso Fakorede, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu Wong. (2010) Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. The American Journal of Cardiology 105:3, 323-332
CrossRef88
Jagtar S. Heir, Vijaya Gottumukkala, Manmeet Singh, Syed Wamique Yusuf, Bernhard Riedel. (2010) Coronary Stents and Noncardiac Surgery: Current Clinical Challenges and Conundrums. Preventive Cardiology 13:1, 8-13
CrossRef89
J. Tacke, E. Lindhoff-Last. (2010) Medikamentöse Therapie bei interventionellen Eingriffen am peripheren Gefäßsystem. Der Radiologe 50:1, 44-47
CrossRef90
Vincenzo Pasceri, Giuseppe Patti, Christian Pristipino, Francesco Pelliccia, Diego Irini, Antonio Varveri, Adriana Roncella, Germano Di Sciascio, Giulio Speciale. (2010) Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef91
William M. Stone, Sailendra G. Naidu, Alyssa Chapital, Samuel R. Money. (2010) Antiplatelet Medications: Old and Emerging Therapies. Annals of Vascular Surgery 24:1, 140-148
CrossRef92
Dominick J. Angiolillo, José Luis Ferreiro. (2010) Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Revista Española de Cardiología 63:1, 60-76
CrossRef93
Bhatt, Deepak L., Lincoff, A. Michael, Gibson, C. Michael, Stone, Gregg W., McNulty, Steven, Montalescot, Gilles, Kleiman, Neal S., Goodman, Shaun G., White, Harvey D., Mahaffey, Kenneth W., Pollack, Charles V. Jr., Manoukian, Steven V., Widimsky, Petr, Chew, Derek P., Cura, Fernando, Manukov, Ivan, Tousek, Frantisek, Jafar, M. Zubair, Arneja, Jaspal, Skerjanec, Simona, Harrington, Robert A., . (2009) Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine 361:24, 2330-2341
Full Text94
Richard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M.M. Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology 54:24, 2261-2276
CrossRef95
Kurt M Reinhart, C. Michael White, William L Baker. (2009) Prasugrel: A Critical Comparison with Clopidogrel. Pharmacotherapy 29:12, 1441-1451
CrossRef96
P.-F. Lesault, E. Teiger. (2009) Voie d’abord radiale et prise en charge des malades sous anticoagulants oraux au long cours en cardiologie interventionnelle. Annales de Cardiologie et d'Angéiologie 58:6, 360-365
CrossRef97
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, A. Kastrati. (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal 30:22, 2714-2721
CrossRef98
Matthew S. Edwards, Matthew A. Corriere. (2009) Contemporary management of atherosclerotic renovascular disease. Journal of Vascular Surgery 50:5, 1197-1210
CrossRef99
Willem Dewilde, Jurriën Ten Berg. (2009) Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). American Heart Journal 158:5, 713-718
CrossRef100
Daniel I. Simon, Sahil A. Parikh. (2009) Hunting for the “Sweet Spot” in P2Y12 Receptor Blockade
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 54:15, 1447-1449
CrossRef101
Daniel McKenzie, Usha Rao, Alex Hobson, Terry Levy, Suneel Talwar, Rosie Swallow. (2009) A novel strategy for managing clopidogrel-induced adverse skin reactions. EuroIntervention 5:4, 470-474
CrossRef102
Robert A. Byrne, Nikolaus Sarafoff, Adnan Kastrati, Albert Schömig. (2009) Drug-Eluting Stents in Percutaneous Coronary Intervention. Drug Safety 32:9, 749-770
CrossRef103
Tatsuhiko Asano, Yoshio Kobayashi, Kenichi Fukushima, Yo Iwata, Hideki Kitahara, Naoki Ishio, Takashi Nakayama, Nakabumi Kuroda, Issei Komuro. (2009) Effect of balloon inflation time on expansion of sirolimus-eluting stent. Heart and Vessels 24:5, 335-339
CrossRef104
Kenichi Sakakura, Norifumi Kubo, Junya Ako, Nahoko Ikeda, Hiroshi Funayama, Taishi Hirahara, Hiroshi Wada, Yoshitaka Sugawara, Takanori Yasu, Masanobu Kawakami, Shin-ichi Momomura. (2009) Clinical features of early recurrent myocardial infarction. Heart and Vessels 24:5, 347-351
CrossRef105
Martine Gilard, Didier Blanchard, Gérard Helft, Didier Carrier, Helene Eltchaninoff, Loic Belle, Gérard Finet, Hervé Le Breton, Jacques Boschat. (2009) Antiplatelet Therapy in Patients With Anticoagulants Undergoing Percutaneous Coronary Stenting (from STENTIng and oral antiCOagulants [STENTICO]). The American Journal of Cardiology 104:3, 338-342
CrossRef106
Tina L. Pinto Slottow, Laurent Bonello, Rekha Gavini, Patricia Beauzile, Steven J. Sushinsky, Mickey Scheinowitz, Kimberly Kaneshige, Zhenyi Xue, Rebecca Torguson, Udaya Tantry, Augusto D. Pichard, Lowell F. Satler, William O. Suddath, Kenneth Kent, Paul Gurbel, Ron Waksman. (2009) Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. The American Journal of Cardiology 104:4, 525-530
CrossRef107
LEROY E. RABBANI, SRINIVAS IYENGAR, GEORGE D. DANGAS, CINDY L. GRINES, DAVID A. COX, EULOGIO GARCIA, JAMES E. TCHENG, JOHN J. GRIFFIN, GIULIO GUAGLIUMI, THOMAS STUCKEY, MARK TURCO, JENNIFER STANT, MARTIN FAHY, ALEXANDRA J. LANSKY, ROXANA MEHRAN, GREGG W. STONE. (2009) Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal of Interventional Cardiology 22:4, 378-384
CrossRef108
William L. Baker, C. Michael White. (2009) Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. American Journal Cardiovascular Drugs 9:4, 213-229
CrossRef109
Sonny Dandona, Robert Roberts. (2009) Genomic view of factors leading to plaque instability. Current Cardiology Reports 11:4, 282-287
CrossRef110
David R. Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines. (2009) Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology 54:2, 95-109
CrossRef111
Richard V. Milani. (2009) Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?. Catheterization and Cardiovascular Interventions 74:S1, S7-S11
CrossRef112
Changqing Gao, Chonglei Ren, Dong Li, Libing Li. (2009) Clopidogrel and Aspirin Versus Clopidogrel Alone on Graft Patency After Coronary Artery Bypass Grafting. The Annals of Thoracic Surgery 88:1, 59-62
CrossRef113
Stephen D. Wiviott, Elliott M. Antman. 2009. Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. , 471-484.
CrossRef114
Hussam Hamdalla and, Steven R. Steinhubl. 2009. The Combination of Anticoagulants and Platelet Inhibitors Postcoronary Stent Implantation. , 555-562.
CrossRef115
Yoichi Sugita, Yoshiaki Suzuki, Kenji Someya, Akira Ogawa, Hiroshi Furuhata, Shinichiro Miyoshi, Tadashi Motomura, Hiroshi Miyamoto, Stephen Igo, Yukihiko Nosé. (2009) Experimental Evaluation of a New Antithrombogenic Stent Using Ion Beam Surface Modification. Artificial Organs 33:6, 456-463
CrossRef116
Doron Zahger, Reuben Ilia. (2009) Coronary stenting in warfarin treated patients. EuroIntervention 5:2, 277-281
CrossRef117
Michelle J. Butler, David Eccleston, David J. Clark, Andrew E. Ajani, Nick Andrianopoulos, Angela Brennan, Gishel New, Alexander Black, Gregory Szto, Chris M. Reid, Bryan P. Yan, James A. Shaw, Anthony M. Dart, Stephen J. Duffy. (2009) The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. American Heart Journal 157:5, 899-907
CrossRef118
Rahul Sakhuja, Deepak L. Bhatt. (2009) Getting real with drug-eluting stents: 5-year follow up of a real-world cohort. American Heart Journal 157:5, 802-804
CrossRef119
Jan Smid, Ruediger Braun-Dullaeus, Meinrad Gawaz, Harald F Langer. (2009) Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiology 5:3, 285-296
CrossRef120
Sergio Manzano-Fernández, Cesar Caro, Francisco Cambronero, Francisco J. Pastor, Francisco Marín, Mariano Valdés-Chavarri. (2009) “Antithrombotic therapy after coronary stenting in patients with indication for oral anticoagulation”. International Journal of Cardiology 134:1, 125-127
CrossRef121
U. Zeymer, J. Senges, R. Zahn. (2009) Antithrombotische Therapie bei Patienten mit Indikation zur oralen Antikoagulation und koronarer Stentimplantation. Clinical Research in Cardiology Supplements 4:S2, 150-153
CrossRef122
Matthew J. Price, Peter B. Berger, Dominick J. Angiolillo, Paul S. Teirstein, Jean-François Tanguay, David E. Kandzari, Christopher P. Cannon, Eric J. Topol. (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. American Heart Journal 157:5, 818-824.e1
CrossRef123
Allison G. Dupont, Don A. Gabriel, Mauricio G. Cohen. (2009) Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research 124:1, 6-13
CrossRef124
Piera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo. (2009) Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:4, 361-369
CrossRef125
Robert A. Byrne, Stefanie Schulz, Julinda Mehilli, Raisuke Iijima, Steffen Massberg, Franz-Josef Neumann, Jurriёn M. ten Berg, Albert Schömig, Adnan Kastrati. (2009) Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal 157:4, 620-624.e2
CrossRef126
Lidia Argüello Viudez. (2009) Los antiagregantes plaquetarios (aspirina y otros, como por ejemplo clopidogrel): ¿incrementan el riesgo de complicaciones hemorrágicas tras la polipectomía endoscópica o tras la esfinterotomía endoscópica y por este motivo deben suspenderse de 7 a 10 días antes de realizar estas técnicas?. Gastroenterología y Hepatología 32:4, 318-320
CrossRef127
K. Pels, P. L. Schwimmbeck, P. Rosenthal, C. Loddenkemper, C. Dang-Heine, U. Rauch, H. Martens, H.-P. Schultheiss, R. Dechend, C. Deiner. (2009) Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. European Journal of Clinical Investigation 39:3, 174-182
CrossRef128
David A. Brown, Edward W. Lee, Christopher T. Loh, Stephen T. Kee. (2009) A New Wave in Treatment of Vascular Occlusive Disease: Biodegradable Stents—Clinical Experience and Scientific Principles. Journal of Vascular and Interventional Radiology 20:3, 315-324
CrossRef129
Guillermo N. Vaccarino, Jorge Thierer, Mariano Albertal, Mariano Vrancic, Fernando Piccinini, Mariano Benzadón, Hernán Raich, Daniel O. Navia. (2009) Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: A propensity score analysis. The Journal of Thoracic and Cardiovascular Surgery 137:2, 309-313
CrossRef130
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Peter B. Berger, Eric J. Topol. (2009) Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 157:2, 369-374
CrossRef131
Mitsuhiro Fujishiro, Ichiro Oda, Yorimasa Yamamoto, Junichi Akiyama, Naoki Ishii, Naomi Kakushima, Junko Fujiwara, Shinji Morishita, Hiroshi Kawachi, Hirokazu Taniguchi, Takuji Gotoda. (2009) Multi-center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan. Journal of Gastroenterology and Hepatology 24:2, 214-218
CrossRef132
Gilles Montalescot, Stephen D Wiviott, Eugene Braunwald, Sabina A Murphy, C Michael Gibson, Carolyn H McCabe, Elliott M Antman. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. The Lancet 373:9665, 723-731
CrossRef133
Giuseppe Patti, Germano Di Sciascio. (2009) Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: A proposed algorithm based on individual risk stratification. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef134
Alexandra J. Lansky, Yoshihiro Tsuchiya, Micheal Brener, Roxana Mehran, Ecaterina Cristea, Cody Pietras, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, Giulio Guagliumi, Thomas Stuckey, Mark Turco, John D. Carroll, Barry D. Rutherford, Martin B. Leon, Jeffrey Moses, Gregg W. Stone. (2008) Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization and Cardiovascular Interventions 72:7, 917-924
CrossRef135
Neal S. Kleiman. (2008) Searching for the Ceiling. JACC: Cardiovascular Interventions 1:6, 628-630
CrossRef136
Stephen J. Lemon, Jeremy D. Flynn, Steven P. Dunn. (2008) Perioperative Management of Antiplatelet Therapy in Patients with Cardiovascular Disease. Orthopedics 31:12, 1210-1213
CrossRef137
Qasim Bashir, Aamir Badruddin, Victor Aletich. (2008) Endovascular Techniques for Stroke Prevention. Neurologic Clinics 26:4, 1099-1127
CrossRef138
N. Sarafoff, G. Ndrepepa, J. Mehilli, K. Dörrler, S. Schulz, R. Iijima, R. Byrne, A. Schömig, A. Kastrati. (2008) Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. Journal of Internal Medicine 264:5, 472-480
CrossRef139
Gregory A. Nuttall, Michael J. Brown, John W. Stombaugh, Peter B. Michon, Matthew F. Hathaway, Kevin C. Lindeen, Andrew C. Hanson, Darrell R. Schroeder, William C. Oliver, David R. Holmes, Charanjit S. Rihal. (2008) Time and Cardiac Risk of Surgery after Bare-metal Stent Percutaneous Coronary Intervention. Anesthesiology 109:4, 588-595
CrossRef140
K. Linni, N. Mader, Th. Hölzenbein. (2008) Competitive strategies for surgery in the treatment of primary internal carotid artery (ICA) stenosis. European Surgery 40:5, 227-238
CrossRef141
Gilles Lemesle, Arnaud Sudre, Thomas Modine, Cédric Delhaye, Guillaume Rosey, Terry Gourlay, Christophe Bauters, Jean-Marc Lablanche. (2008) High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheterization and Cardiovascular Interventions 72:4, 470-478
CrossRef142
S. S. Jolly, J. Pogue, K. Haladyn, R. J.G. Peters, K. A.A. Fox, A. Avezum, B. J. Gersh, H. J. Rupprecht, S. Yusuf, S. R. Mehta. (2008) Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal 30:8, 900-907
CrossRef143
S. R. Steinhubl, P. B. Berger. (2008) Aspirin following PCI: too much of a good thing?. European Heart Journal 30:8, 882-884
CrossRef144
Michael A. Brown, Trung H. D. Tran, Ronald J. Krone. (2008) Drug-eluting stents: Are they still the answer?. Current Cardiovascular Risk Reports 2:5, 334-341
CrossRef145
John P Girod, Suresh R Mulukutla, Oscar C Marroquin. (2008) Off-label use of stents: bare-metal versus drug-eluting stents. Expert Review of Cardiovascular Therapy 6:8, 1095-1106
CrossRef146
Lisa T. Newsome, Michael A. Kutcher, Roger L. Royster. (2008) Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesthesia & Analgesia 107:2, 552-569
CrossRef147
MARC COHEN, JAMES HOEKSTRA, ROBERT GIUGLIANO, CHRISTOPHER B. GRANGER, PAUL A. GURBEL, JUDD E. HOLLANDER, STEVEN V. MANOUKIAN, CHARLES V. POLLACK, JR, JORGE F. SAUCEDO. (2008) Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. Journal of Interventional Cardiology 21:4, 283-299
CrossRef148
P. Roy, D. H. Steinberg, S. J. Sushinsky, T. Okabe, T. L. Pinto Slottow, K. Kaneshige, Z. Xue, L. F. Satler, K. M. Kent, W. O. Suddath, A. D. Pichard, N. J. Weissman, J. Lindsay, R. Waksman. (2008) The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. European Heart Journal 29:15, 1851-1857
CrossRef149
Colin M. Barker, Matthew J. Price. (2008) Antiplatelet therapy in acute coronary syndromes. Current Cardiology Reports 10:4, 327-333
CrossRef150
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, Y. Sakata. (2008) Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. European Heart Journal 29:14, 1729-1738
CrossRef151
Victor L. Serebruany, Alex I. Malinin, James J. Ferguson, Javad Vahabi, Dan Atar, Charles H. Hennekens. (2008) Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129 314 patients. Fundamental & Clinical Pharmacology 22:3, 315-321
CrossRef152
JOSÉ VALENCIA, VICENTE MAINAR, PASCUAL BORDES, JAVIER PINEDA, SILVIA GÓMEZ, FRANCISCO SOGORB. (2008) Observance of Antiplatelet Therapy after Stent Implantation in Patients under Chronic Oral Anticoagulant Treatment. Journal of Interventional Cardiology 21:3, 218-224
CrossRef153
Marc S. Sabatine, Hussam N. Hamdalla, Shamir R. Mehta, Keith A.A. Fox, Eric J. Topol, Steven R. Steinhubl, Christopher P. Cannon. (2008) Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal 155:5, 910-917
CrossRef154
Akira Tamura, Toru Watanabe, Kazuhiro Shinozaki, Munenori Kotoku, Shoji Yano, Junichi Kadota. (2008) Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation. International Journal of Cardiology 126:1, 79-83
CrossRef155
Neal S. Kleiman. (2008) Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel?
CrossRef156
C.M. Bünger, N. Grabow, K. Sternberg, L. Ketner, C. Kröger, M. Goosmann, H.J. Kreutzer, B. Lorenzen, K.H. Hauenstein, K.-P. Schmitz, H. Ince, D. Lootz, E. Klar, W. Schareck. (2008) Temporäre Implantate für die endovaskuläre Applikation. Gefässchirurgie 13:2, 99-106
CrossRef157
Stephen D Wiviott, Eugene Braunwald, Carolyn H McCabe, Ivan Horvath, Matyas Keltai, Jean-Paul R Herrman, Frans Van de Werf, William E Downey, Benjamin M Scirica, Sabina A Murphy, Elliott M Antman. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. The Lancet 371:9621, 1353-1363
CrossRef158
Michael J. Rinaldi, Ajay J. Kirtane, Robert N. Piana, Ronald P. Caputo, Paul C. Gordon, John J. Lopez, Harold L. Dauerman, Thomas J. Ryan, Francis J. Kiernan, Donald E. Cutlip, Kalon K.L. Ho, C. Michael Gibson, Sabina A. Murphy, David J. Cohen. (2008) Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: Results of a multicenter case-control study with 145 thrombosis events. American Heart Journal 155:4, 654-660
CrossRef159
Dean J. Kereiakes, Paul A. Gurbel. (2008) Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 1:2, 111-121
CrossRef160
Julio García Tejada, Agustín Albarrán González-Trevilla. (2008) Stents y trombosis. Medicina Clínica 130:5, 175-176
CrossRef161
Juan M. Ruiz-Nodar, Francisco Marín, José Antonio Hurtado, José Valencia, Eduardo Pinar, Javier Pineda, Juan Ramón Gimeno, Francisco Sogorb, Mariano Valdés, Gregory Y.H. Lip. (2008) Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Journal of the American College of Cardiology 51:8, 818-825
CrossRef162
Steven Francescone, Jonathan L. Halperin. (2008) “Triple Therapy” or Triple Threat?. Journal of the American College of Cardiology 51:8, 826-827
CrossRef163
Phillip Owen, John Garner, Lawrence Hergott, Robert Lee Page. (2008) Clopidogrel Desensitization: Case Report and Review of Published Protocols. Pharmacotherapy 28:2, 259-270
CrossRef164
Martin K. Stiles, Omar H. Dabbous, Keith A.A. Fox. (2008) Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE). Heart, Lung and Circulation 17:1, 5-8
CrossRef165
Tracy Y. Wang, Lee A. Robinson, Fang-Shu Ou, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, Sidney C. Smith, Eric D. Peterson, Richard C. Becker. (2008) Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. American Heart Journal 155:2, 361-368
CrossRef166
Harold L. Dauerman. (2008) Percutaneous Coronary Intervention Pharmacology. Journal of the American College of Cardiology 51:7, 698-700
CrossRef167
JOHN M. GALLA, A. MICHAEL LINCOFF. 2008. Adjunctive pharmacotherapy during PCI. , 53-64.
CrossRef168
Marcus Shaker, Ano Lobb, Pamela Jenkins, Daniel O'Rourke, Steve K. Takemoto, Salil Sheth, Thomas Burroughs, Mark S. Dykewicz. (2008) An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology 121:1, 81-87
CrossRef169
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef170
D. Martí Sánchez, N. Dedieu, L. Salido Tahoces, J.L. Mestre Barceló, J. Pey Illera. (2008) Trombosis del stent. Revista Clínica Española 208:1, 29-32
CrossRef171
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef172
Hye Won Lee. (2008) Perioperative management for patients undergoing noncardiac surgery after percutaneous coronary intervention. Korean Journal of Anesthesiology 55:1, 1
CrossRef173
Ajay J. Kirtane, Martin B. Leon. (2007) Clinical Use of Sirolimus-Eluting Stents. Cardiovascular Drug Reviews 25:4, 316-332
CrossRef174
JEFFREY J. POPMA, BONNIE WEINER, MICHAEL J. COWLEY, CHARLES SIMONTON, DAN McCORMICK, TED FELDMAN. (2007) FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. Journal of Interventional Cardiology 20:6, 425-446
CrossRef175
Joseph A. Jakubowski, Kenneth J. Winters, Hideo Naganuma, Lars Wallentin. (2007) Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. Cardiovascular Drug Reviews 25:4, 357-374
CrossRef176
Girish R. Mood, Deepak L. Bhatt. (2007) Clopidogrel and risk for acute coronary events. Current Atherosclerosis Reports 9:5, 401-408
CrossRef177
John M Galla, A Michael Lincoff. (2007) The role of clopidogrel in the management of ischemic heart disease. Current Opinion in Internal Medicine 6:5, 454-460
CrossRef178
Daniel I. Simon, Alvin H. Schmaier. (2007) Sweet and Sticky. Journal of the American College of Cardiology 50:16, 1548-1550
CrossRef179
Yoshiko Tamai, Tomoko Komatsu-Ishizawa, Hideki Takami, Hitoshi Nakajima, Shinsaku Fukuda, Akihiro Munakata. (2007) MANAGEMENT OF ANTIPLATELET THERAPY FOR ENDOSCOPIC PROCEDURES: OPTIMAL CESSATION PERIOD OF ANTIPLATELET THERAPY FOR JAPANESE. Digestive Endoscopy 19:4, 161-166
CrossRef180
Hector M. Medina, Deepak L. Bhatt. (2007) Evolution of Anticoagulant and Antiplatelet Therapy: Benefits and Risks of Contemporary Pharmacologic Agents and Their Implications for Myonecrosis and Bleeding in Percutaneous Coronary Intervention. Clinical Cardiology 30:S2, II4-II15
CrossRef181
Steeve Brulotte, Mario Sénéchal, Paul Poirier, Can Manh Nguyen, Ariane Lemieux, Julien Magne, Sébastien Bergeron. (2007) Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute. Canadian Journal of Cardiology 23, 80B-83B
CrossRef182
Giulio Guagliumi, Giuseppe Musumeci, Roberta Rossini, Leonardo Bolognese, Arturo Giordano, Antonio Marzocchi, Angelo Ramondo, Giuseppe Sangiorgi, Corrado Tamburino, Fabrizio Tomai, Stefano De Servi. (2007) Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. Journal of Cardiovascular Medicine 8:10, 782-791
CrossRef183
M. Zimarino, G. Renda, R. Caterina. (2007) Triple antithrombotic therapy with aspirin, clopidogrel and warfarin — a persisting dilemma. Internal and Emergency Medicine 2:3, 163-164
CrossRef184
Gregory Ducrocq, Victor Serebruany, Jean-Francois Tanguay. (2007) Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Expert Review of Cardiovascular Therapy 5:5, 939-953
CrossRef185
Rajeev Garg, Barry F. Uretsky, Eli I. Lev. (2007) Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 70:3, 388-406
CrossRef186
Chang-Bum Park, Myeong-ki Hong, Young-Hak Kim, Duk-Woo Park, Ki-Hoon Han, Cheol Whan Lee, Duck-Hyun Kang, Jae-Kwan Song, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park. (2007) Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. International Journal of Cardiology 120:3, 387-390
CrossRef187
Willem Dewilde, JM ten Berg. (2007) Antithrombotic dilemma. Future Cardiology 3:5, 511-513
CrossRef188
Georgios Sianos, Michail I. Papafaklis, Joost Daemen, Sofia Vaina, Carlos A. van Mieghem, Ron T. van Domburg, Lampros K. Michalis, Patrick W. Serruys. (2007) Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, 573-583
CrossRef189
Yu-Min P. Shen, Eugene P. Frenkel. (2007) Acquired Platelet Dysfunction. Hematology/Oncology Clinics of North America 21:4, 647-661
CrossRef190
Diane E. Head, Joshua J. Sebranek, Cameron Zahed, Douglas B. Coursin, Richard C. Prielipp. (2007) A tale of two stents: perioperative management of patients with drug-eluting coronary stents. Journal of Clinical Anesthesia 19:5, 386-396
CrossRef191
Kagari Murasaki, Masatoshi Kawana, Satoshi Murasaki, Yukio Tsurumi, Kenjiro Tanoue, Nobuhisa Hagiwara, Hiroshi Kasanuki. (2007) High P-selectin expression and low CD36 occupancy on circulating platelets are strong predictors of restenosis after coronary stenting in patients with coronary artery disease. Heart and Vessels 22:4, 229-236
CrossRef192
Ronen Jaffe, Bradley H. Strauss. (2007) Late and Very Late Thrombosis of Drug-Eluting Stents. Journal of the American College of Cardiology 50:2, 119-127
CrossRef193
P. Fontana, J.-L. Reny. (2007) New Antiplatelet Strategies in Atherothrombosis and Their Indications. European Journal of Vascular and Endovascular Surgery 34:1, 10-17
CrossRef194
Jonathan D. Rich, Stephen D. Wiviott. (2007) New antiplatelet therapies for acute coronary syndromes. Current Cardiology Reports 9:4, 303-311
CrossRef195
Jean-Pierre Dery, Mark E. Campbell, Jasmine Mathias, Karen S. Pieper, Robert A. Harrington, Mina Madan, C. Michael Gibson, Thaddeus R. Tolleson, J. Conor O'Shea, James E. Tcheng, . (2007) Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial. Catheterization and Cardiovascular Interventions 70:1, 44-51
CrossRef196
J. W. EIKELBOOM, J. HIRSH. (2007) Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. Journal of Thrombosis and Haemostasis 5, 255-263
CrossRef197
E. VAN BELLE, S. SUSEN, B. JUDE, M. E. BERTRAND. (2007) Drug-eluting stents: trading restenosis for thrombosis?. Journal of Thrombosis and Haemostasis 5, 238-245
CrossRef198
Emmanouil S. Brilakis, Subhash Banerjee, Peter B. Berger. (2007) Perioperative Management of Patients With Coronary Stents. Journal of the American College of Cardiology 49:22, 2145-2150
CrossRef199
Gudjon Karlsson, Jalees Rehman, Vijay Kalaria, Jeffrey A. Breall. (2007) Increased incidence of stent thrombosis in patients with cocaine use. Catheterization and Cardiovascular Interventions 69:7, 955-958
CrossRef200
Tina L. Pinto Slottow, Ron Waksman. (2007) Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheterization and Cardiovascular Interventions 69:7, 1064-1074
CrossRef201
Sheila A Doggrell. (2007) Clopidogrel use with stenting. Expert Opinion on Pharmacotherapy 8:9, 1399-1402
CrossRef202
William J. Mauermann, Kent H. Rehfeldt, Malcolm R. Bell, Stuart M. Lowson. (2007) Percutaneous Coronary Interventions and Antiplatelet Therapy in the Perioperative Period. Journal of Cardiothoracic and Vascular Anesthesia 21:3, 436-442
CrossRef203
Ulrich Sigwart. (2007) Drug-Eluting Stents: Some Thoughts From Old Europe. The American Heart Hospital Journal 5:3, 135-137
CrossRef204
Deborah DeEugenio, Louis Kolman, Matthew DeCaro, Jocelyn Andrel, Inna Chervoneva, Phu Duong, Linh Lam, Christopher McGowan, Grace Lee, Mark DeCaro, Nicholas Ruggiero, Shalabh Singhal, Arnold Greenspon. (2007) Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long-Term Warfarin Therapy. Pharmacotherapy 27:5, 691-696
CrossRef205
G. E. Kikano, M. T. Brown. (2007) Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician. Mayo Clinic Proceedings 82:5, 583-593
CrossRef206
Andrew J Lucking, David E Newby. (2007) Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 8:6, 759-776
CrossRef207
Giuseppe G.L. Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Marco Valgimigli, Antonio Abbate, Giuseppe Sangiorgi, Claudio Moretti, Imad Sheiban. (2007) Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. American Heart Journal 153:4, 587-593
CrossRef208
ANDREW J. BOYLE, MICHAEL Y. CHAN, JOUD DIB, NAVIN K. KAPUR, SANDRA KRAFT, REGIS VAILLANT, JAMES S. WHITING, JON R. RESAR. (2007) Assessment of a Novel Angiographic Image Stabilization System for Percutaneous Coronary Intervention. Journal of Interventional Cardiology 20:2, 153-157
CrossRef209
Dominick J. Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, Fernando Alfonso, Carlos Macaya, Theodore A. Bass, Marco A. Costa. (2007) Variability in Individual Responsiveness to Clopidogrel. Journal of the American College of Cardiology 49:14, 1505-1516
CrossRef210
Dominick J Angiolillo. (2007) Antiplatelet therapy in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 124-131
CrossRef211
B. ALEIL, G. ROCHOUX, J.-P. MONASSIER, J.-P. CAZENAVE, C. GACHET. (2007) Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. Journal of Thrombosis and Haemostasis 5:4, 879-881
CrossRef212
Joseph A. Jakubowski, Nobuko Matsushima, Fumitoshi Asai, Hideo Naganuma, John T. Brandt, Takashi Hirota, Stephen Freestone, Kenneth J. Winters. (2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y 12 inhibitor, compared with clopidogrel in healthy humans. British Journal of Clinical Pharmacology 63:4, 421-430
CrossRef213
S. M. Picker, T. Kaleta, K. Hekmat, S. Kampe, B. S. Gathof. (2007) Antiplatelet therapy preceding coronary artery surgery. European Journal of Anaesthesiology 24:4, 332-339
CrossRef214
R. Zambahari, O-H Kwok, S. Javier, K. H. Mak, S. Piyamitr, H. Q. Tri Ho, J. J. Hwang, R. Suryawan, W. H. Chow. (2007) Clinical use of clopidogrel in acute coronary syndrome. International Journal of Clinical Practice 61:3, 473-481
CrossRef215
Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Jeffrey Popma, Joerg Koglin, Keith D. Dawkins, Gregg W. Stone. (2007) Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent. Journal of the American College of Cardiology 49:10, 1043-1051
CrossRef216
Nicholas E. Walker, Mary B. Fasano, Ryan A. Hobbs, Phillip A. Horwitz. (2007) Clopidogrel Desensitization Protocol for the Treatment of Thienopyridine Hypersensitivity. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 6:1, 26-29
CrossRef217
Cindy L. Grines, Robert O. Bonow, Donald E. Casey,, Timothy J. Gardner, Peter B. Lockhart, David J. Moliterno, Patrick O'Gara, Patrick Whitlow. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheterization and Cardiovascular Interventions 69:3, 334-340
CrossRef218
C GRINES, R BONOW, D CASEYJR, T GARDNER, P LOCKHART, D MOLITERNO, P OGARA, P WHITLOW. (2007) Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery StentsA Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians
CrossRef219
Gurpreet Sandhu, Brendan Doyle, Ripudamanjit Singh, Malcolm Bell, John Bresnahan, Verghese Mathew, David Holmes, Amir Lerman, Charanjit Rihal. (2007) Frequency, Etiology, Treatment, and Outcomes of Drug-Eluting Stent Thrombosis During One Year of Follow-Up. The American Journal of Cardiology 99:4, 465-469
CrossRef220
Aaron V. Kaplan. (2007) Double barrel stenting of the left main: Proceed with caution. Catheterization and Cardiovascular Interventions 69:2, 216-217
CrossRef221
Seung-Jung Park, Seung-Whan Lee. (2007) Optimal management of platelet function after coronary stenting. Current Treatment Options in Cardiovascular Medicine 9:1, 37-45
CrossRef222
Dominick J Angiolillo. (2007) ADP Receptor Antagonism. American Journal of Cardiovascular Drugs 7:6, 423-432
CrossRef223
Marco Cattaneo. (2007) Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy 5:1, 45-55
CrossRef224
Paul A. Gurbel, Kevin P. Bliden, Kirk Guyer, Nikhil Aggarwal, Udaya S. Tantry. (2007) Delayed thrombin-induced platelet–fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thrombosis Research 119:5, 563-570
CrossRef225
Ronen Jaffe, David A. Halon, Judith Carmeli, Basil S. Lewis. (2007) Prolonged intravenous eptifibatide infusion for prevention of coronary stent thrombosis. International Journal of Cardiology 114:3, 409-411
CrossRef226
Paul A. Gurbel, Kevin P. Bliden, Amena Etherington, Udaya S. Tantry. (2007) Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thrombosis Research 121:1, 107-115
CrossRef227
Paweł Buszman, Iwona Szkróbka, Agata Gruszka, Radosław Parma, Zofia Tendera, Blanka Leśko, Mirosław Wilczyński, Tomasz Bochenek, Wojciech Wojakowski, Andrzej Bochenek, Michał Tendera. (2007) Comparison of Effectiveness of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Ischemic Cardiomyopathy. The American Journal of Cardiology 99:1, 36-41
CrossRef228
Saeko Takahashi, Hideaki Kaneda, Shinji Tanaka, Yusuke Miyashita, Takaaki Shiono, Yoshio Taketani, Hiroshi Domae, Junya Matsumi, Shingo Mizuno, Yoshiyasu Minami, Kazuya Sugitatsu, Shigeru Saito. (2007) Late Angiographic Stent Thrombosis After Sirolimus-Eluting Stent Implantation. Circulation Journal 71:2, 226-228
CrossRef229
Hun-Jun Park, Ki-Bae Seung, Pum Joon Kim, Hyun-Hee Kang, Chan-Seok Park, Uk-Hyun Kil, Min-Seok Choi, Sang-Hong Baek, Jae-Hyung Kim, Kyu-Bo Choi. (2007) Intracoronary Stent Deployment without Antiplatelet Agents in a Patient with Idiopathic Thrombocytopenic Purpura. Korean Circulation Journal 37:2, 87
CrossRef230
Jang-Young Kim, Junghan Yoon. (2007) Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal 37:4, 135
CrossRef231
O. Cuyun-Lira, M. Kaneko, T. Takafuta, K. Satoh, M. Ohnishi, Y. Yatomi, Y. Ozaki. (2007) Inhibitory effects of ticlopidine on platelet function as assessed by three different methods. European Journal of Pharmaceutical Sciences 30:1, 21-25
CrossRef232
Harold L. Dauerman. (2006) Drug Eluting Stents. Coronary Artery Disease 17:8, 657-659
CrossRef233
Huyen Tran, Shamir R Mehta, John W Eikelboom. (2006) Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management 2:4, 379-387
CrossRef234
Aparna R. Dalal, Stanlies D’;Souza, Mark S. Shulman. (2006) Brief review: Coronary drug-eluting stents and anesthesia. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:12, 1230-1243
CrossRef235
Gérard Helft, Martine Gilard, Claude Le Feuvre, Azfar G Zaman. (2006) Drug Insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nature Clinical Practice Cardiovascular Medicine 3:12, 673-680
CrossRef236
Robert A. Harrington, Robert M. Califf. (2006) Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting. Journal of the American College of Cardiology 48:12, 2592-2595
CrossRef237
Glen E Cooke, Pascal J Goldschmidt-Clermont. (2006) The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opinion on Drug Safety 5:6, 815-826
CrossRef238
Glenn N Levine, Peter B Berger, David J Cohen, Andrew O Maree, Kenneth Rosenfield, Barbara S Wiggins, Sarah A Spinler. (2006) Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals. Pharmacotherapy 26:11, 1537-1556
CrossRef239
D Charytan, R E Kuntz. (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney International
CrossRef240
2006. Post-Myocardial Infarction. .
CrossRef241
SEIFEDDIN S. EL-JACK, SIMON R. DIXON, CINDY L. GRINES, WILLIAM W. O'NEILL. (2006) Bifurcation Stenting: Unnecessary Challenge or a Last Frontier in Intervention. Journal of Interventional Cardiology 19:s5, S27-S39
CrossRef242
JOSEPH P. CARROZZA. (2006) Duration of Clopidogrel Therapy with Drug-Eluting Stents. Journal of Interventional Cardiology 19:s5, S40-S46
CrossRef243
M. Grebe. (2006) Gerinnungsaktive Medikamente zur Sekundärprophylaxe bei pAVK. Gefässchirurgie 11:5, 341-346
CrossRef244
Adnan K. Chhatriwalla, Deepak L. Bhatt. 2006. Anticoagulation and Antiplatelet Agents. , 501-524.
CrossRef245
Philip R. Liebson. (2006) CHARISMA and TROPHY. Preventive Cardiology 9:4, 235-238
CrossRef246
Ilias Dalainas, Giovanni Nano, Paolo Bianchi, Silvia Stegher, Giovanni Malacrida, Domenico G. Tealdi. (2006) Dual Antiplatelet Regime Versus Acetyl-acetic Acid for Carotid Artery Stenting. CardioVascular and Interventional Radiology 29:4, 519-521
CrossRef247
Karen E Thomas, Duane S Pinto. (2006) Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nature Clinical Practice Cardiovascular Medicine 3:8, 416-417
CrossRef248
Avital Porter, Yuval Konstantino, Zaza Iakobishvili, Leeor Shachar, Alexander Battler, David Hasdai. (2006) Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 68:1, 56-61
CrossRef249
Alanna Coolong, Laura Mauri. (2006) Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?. Current Cardiology Reports 8:4, 267-271
CrossRef250
Neal A. Scott. (2006) Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Advanced Drug Delivery Reviews 58:3, 358-376
CrossRef251
Antònia Agustí, Montserrat Bosch. (2006) Prevención de la enfermedad aterotrombótica con la combinación de dos antiagregantes plaquetarios. Medicina Clínica 127:4, 153-155
CrossRef252
Hidehiko Hara, Masato Nakamura, Julio C. Palmaz, Robert S. Schwartz. (2006) Role of stent design and coatings on restenosis and thrombosis. Advanced Drug Delivery Reviews 58:3, 377-386
CrossRef253
Dalton S. McLean, Christopher P. Cannon. (2006) The Clinical Potential of a Point-of-Care Assay to Assess Interindividual Variability in Platelet Aggregation Among Patients Taking Clopidogrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:2, 103-113
CrossRef254
J.F. Meco, X. Pintó. (2006) Controversia terapéutica: clopidogrel y estatinas. Clínica e Investigación en Arteriosclerosis 18, 34-48
CrossRef255
Dalton S McLean, Christopher P Cannon. (2006) A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiology 2:3, 255-267
CrossRef256
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef257
Udaya S Tantry, Amena Etherington, Kevin P Bliden, Paul A Gurbel. (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiology 2:3, 343-366
CrossRef258
G. W. Stone, H. D. Aronow. (2006) Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings 81:5, 641-652
CrossRef259
Pfeffer, Marc A., Jarcho, John A., . (2006) The Charisma of Subgroups and the Subgroups of CHARISMA. New England Journal of Medicine 354:16, 1744-1746
Full Text260
Ulrich Sigwart. (2006) Drug-Eluting Stents Are Safe and Effective. Journal of the American College of Cardiology 47:7, 1361-1362
CrossRef261
Rakesh P. Mehta, Matthew S. Johnson. (2006) Update on Anticoagulant Medications for the Interventional Radiologist. Journal of Vascular and Interventional Radiology 17:4, 597-612
CrossRef262
Andrea Rubboli, Giuseppe Di Pasquale. (2006) Optimal antithrombotic treatment in patients with an indication for long-term anticoagulation undergoing coronary artery stenting. Future Cardiology 2:2, 205-213
CrossRef263
JAMES J. GLAZIER, J. RICHARD SPEARS, MELVIN C. MURPHY. (2006) Interventional Approach to Recurrent Myocardial Infarction in HIV-1 Infection. Journal of Interventional Cardiology 19:1, 93-98
CrossRef264
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, e1-e121
CrossRef265
Aaron L Baggish, Marc S Sabatine. (2006) Clopidogrel use in coronary artery disease. Expert Review of Cardiovascular Therapy 4:1, 7-15
CrossRef266
Ariel Roguin, Ehud Grenadier. (2006) Stent‐based percutaneous coronary interventions in small coronary arteries. Acute Cardiac Care 8:2, 70-74
CrossRef267
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef268
Monisha Dutta, Elias Hanna, Pranab Das, Steven R. Steinhubl. (2006) Incidence and Prevention of Ischemic Stroke following Myocardial Infarction: Review of Current Literature. Cerebrovascular Diseases 22:5-6, 331-339
CrossRef269
Osamu MASUO, Tomoaki TERADA, Yoshikazu MATSUDA, Mitsuhiro OGURA, Tomoyuki TSUMOTO, Hiroo YAMAGA, Toru ITAKURA. (2006) Successful Recanalization by In-Stent Percutaneous Transluminal Angioplasty With Distal Protection for Acute Carotid Stent Thrombosis-Case Report-. Neurologia medico-chirurgica 46:10, 495-499
CrossRef270
Lisa K Jennings. (2005) Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology 1:4, 727-737
CrossRef271
Anna Ringborg, Peter Lindgren, Bengt Jönsson. (2005) The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. The European Journal of Health Economics 6:4, 354-362
CrossRef272
Ichiro Ieiri, Miyuki Kimura, Shin Irie, Akinori Urae, Kenji Otsubo, Takashi Ishizaki. (2005) Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenetics and Genomics 15:12, 851-859
CrossRef273
Sean M Donahoe, Marc S Sabatine. (2005) Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 751-761
CrossRef274
Peter N. Ruygrok, John A. Ormiston, James T. Stewart, Mark W.I. Webster, Seif El Jack, Stephanie Simpson-Plaumann, I. Patrick Kay, Tony M. Chou. (2005) Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition. Catheterization and Cardiovascular Interventions 66:2, 185-191
CrossRef275
Jehangir N. Din, Keith A.A. Fox. (2005) Clopidogrel in Acute Coronary Heart Disease. The American Heart Hospital Journal 3:4, 234-242
CrossRef276
Sean C. Beinart, Paul Kolm, Emir Veledar, Zefeng Zhang, Elizabeth M. Mahoney, Olivier Bouin, Sylvie Gabriel, Joseph Jackson, Roland Chen, Jaime Caro, Steven Steinhubl, Eric Topol, William S. Weintraub. (2005) Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 46:5, 761-769
CrossRef277
Daniel C Bezerra, Julien Bogousslavky. (2005) Clopidogrel: cardiologists’ panacea or neurologists’ headache?. Future Cardiology 1:5, 579-590
CrossRef278
Tomoko Komatsu, Yoshiko Tamai, Hideki Takami, Kazufumi Yamagata, Shinsaku Fukuda, Akihiro Munakata. (2005) Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. Journal of Gastroenterology 40:7, 698-707
CrossRef279
Junbo Ge, Yaling Han, Hong Jiang, Baogui Sun, Jiyan Chen, Shuyang Zhang, Zhimin Du. (2005) RACTS: A Prospective Randomized Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting. Journal of Cardiovascular Pharmacology 46:2, 162-166
CrossRef280
D. R. PHILLIPS, P. B. CONLEY, U. SINHA, P. ANDRE. (2005) Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis 3:8, 1577-1589
CrossRef281
STEPHEN J. MATTICHAK, PAMELA S. REED, MICHAEL J. GALLAGHER, JUDITH A. BOURA, WILLIAM W. O'NEILL, JOEL K. KAHN. (2005) Evaluation of Safety of Warfarin in Combination with Antiplatelet Therapy for Patients Treated with Coronary Stents for Acute Myocardial Infarction. Journal of Interventional Cardiology 18:3, 163-166
CrossRef282
(2005) Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Revista Española de Cardiología 58:6, 679-728
CrossRef283
Jin Yang Joo, Jung Yong Ahn, Young Sun Chung, Sang Sup Chung, Sang Heum Kim, Pyeong Ho Yoon, Ok Joon Kim. (2005) Therapeutic Endovascular Treatments for Traumatic Carotid Artery Injuries. The Journal of Trauma: Injury, Infection, and Critical Care 58:6, 1159-1166
CrossRef284
B. Napoléon, B. Boneu, L. Maillard, Ch. M. Samama, J. F. Schved, G. Gay, Th. Ponchon, D. Sautereau, J. M. Canard. (2005) La prise en charge des patients sous anticoagulants ou sous agents antiplaquettaires avant une endoscopie digestive. Acta Endoscopica 35:3, 351-363
CrossRef285
Begoña Benito, Mónica Masotti, Amadeo Betriu. (2005) Avances en el tratamiento farmacológico coadyuvante en la intervención coronaria. Revista Española de Cardiología 58:6, 729-743
CrossRef286
Peter N Ruygrok, Tony M Chou. (2005) StarClose™ femoral arteriotomy closure device: an advance in arterial closure. Expert Review of Medical Devices 2:3, 247-252
CrossRef287
F.M. McKevitt, M.S. Randall, T.J. Cleveland, P.A. Gaines, K.T. Tan, G.S. Venables. (2005) The Benefits of Combined Anti-platelet Treatment in Carotid Artery Stenting. European Journal of Vascular and Endovascular Surgery 29:5, 522-527
CrossRef288
Alain J Nordmann, Heiner Bucher, P Hengstler, Thomas Harr, James Young, Alain J Nordmann. 2005. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. .
CrossRef289
Raimondo Ascione, Arup Ghosh, Chris A. Rogers, Alan Cohen, Chris Monk, Gianni D. Angelini. (2005) In-Hospital Patients Exposed to Clopidogrel Before Coronary Artery Bypass Graft Surgery: A Word of Caution. The Annals of Thoracic Surgery 79:4, 1210-1216
CrossRef290
Yasuhiko Akiyama, Ichiro Nakahara, Masahito Tanaka, Yasushi Iwamuro, Junya Hayashi, Kei Harada, Motoaki Fujimoto. (2005) Urgent Endovascular Stent-Graft Placement for a Ruptured Traumatic Pseudoaneurysm of the Extracranial Carotid Artery. The Journal of Trauma: Injury, Infection, and Critical Care 58:3, 624-627
CrossRef291
Ronak S. Kanani, Joseph M. Garasic. (2005) Lower extremity arterial occlusive disease: Role of percutaneous revascularization. Current Treatment Options in Cardiovascular Medicine 7:2, 99-107
CrossRef292
Amar Mohammad Salam. (2005) The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel. Expert Opinion on Investigational Drugs 14:3, 335-338
CrossRef293
SAMUEL O. JONES, ROBERT E. ECKART, ERIC A. SHRY, DANIEL E. SIMPSON. (2005) Review of Subacute Stent Thrombosis Following Percutaneous Coronary Intervention at a Low-Volume Catheterization Laboratory. Journal of Interventional Cardiology 18:1, 11-15
CrossRef294
Sepehr Sani, Kirk W. Jobe, Demetrius K. Lopes. (2005) Treatment of wide-necked cerebral aneurysms with the Neuroform2 Treo stent. Neurosurgical FOCUS 18:2, 1-5
CrossRef295
Harry L. Messmore, Walter P. Jeske, William Wehrmacher, Erwin Coyne, Sohrab Mobarhan, Leslie Cho, Fred S. Leya, John F. Moran. (2005) Antiplatelet Agents: Current Drugs and Future Trends. Hematology/Oncology Clinics of North America 19:1, 87-117
CrossRef296
Abdallah G Rebeiz, Joseph Adams, Robert A Harrington. (2005) Interventional Cardiovascular Pharmacotherapy. American Journal of Cardiovascular Drugs 5:2, 93-102
CrossRef297
Pietro Di Pasquale, Sergio Cannizzaro, Sebastiano Scalzo, Francesco Giambanco, Giuseppe Tricoli, Sergio Fasullo, Salvatore Paterna. (2005) Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients. Heart Drug 5:4, 187-192
CrossRef298
Brendan Duffy, Deepak L Bhatt. (2005) Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 5:5, 307-318
CrossRef299
F. Herbstreit, J. Peters. (2005) Spinal anaesthesia despite combined clopidogrel and aspirin therapy in a patient awaiting lung transplantation: effects of platelet transfusion on clotting tests. Anaesthesia 60:1, 85-87
CrossRef300
Marco Zimarino, Giulia Renda, Raffaele De Caterina. (2005) Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. Drugs 65:6, 725-732
CrossRef301
Bryan PY Yan, David J Clark, Andrew E Ajani. (2005) Oral antiplatelet therapy and percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 6:1, 3-12
CrossRef302
Andrea Rubboli, Milena Milandri, Cristina Castelvetri, Benilde Cosmi. (2005) Meta-Analysis of Trials Comparing Oral Anticoagulation and Aspirin versus Dual Antiplatelet Therapy after Coronary Stenting. Cardiology 104:2, 101-106
CrossRef303
Mustafa Ozkan, Cemal Sag, Mehmet Yokusoglu, Mehmet Uzun, Oben Baysan, Kursad Erinc, Ersoy Isik. (2005) The Effect of Tirofiban and Clopidogrel Pretreatment on Outcome of Old Saphenous Vein Graft Stenting in Patients with Acute Coronary Syndromes. The Tohoku Journal of Experimental Medicine 206:1, 7-13
CrossRef304
David E. Kandzari, Peter B. Berger, Adnan Kastrati, Steven R. Steinhubl, Julinda Mehilli, Franz Dotzer, Jurriën M. ten Berg, Franz-Josef Neumann, Hildegard Bollwein, Josef Dirschinger, Albert Schömig. (2004) Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. Journal of the American College of Cardiology 44:11, 2133-2136
CrossRef305
David E. Allie, Chris J. Hebert, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. Khan, Esmond A. Barker, Michael W. McElderry, Muhammad A. Khan, Peter S. Fail, Samuel J. Stagg, Elena V. Mitran, Gary Chaisson, Sonja D. Allie, Adam A. Allie, Craig M. Walker. (2004) Novel simultaneous combination chemical thrombolysis/rheolytic thrombectomy therapy for acute critical limb ischemia: The power-pulse spray technique. Catheterization and Cardiovascular Interventions 63:4, 512-522
CrossRef306
Andrew J. Feiring, Amy A. Wesolowski, Susan Lade. (2004) Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication. Journal of the American College of Cardiology 44:12, 2307-2314
CrossRef307
Paul P. Dobesh, Zachary A. Stacy, Alexander J. Ansara, Jason M. Enders. (2004) Drug-Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease. Pharmacotherapy 24:11, 1554-1577
CrossRef308
Arvind K. Sharma, Andrew E. Ajani, Shadi M. Hamwi, Parimal Maniar, Shilen V. Lakhani, Ron Waksman, Joseph Lindsay. (2004) Major noncardiac surgery following coronary stenting: When is it safe to operate?. Catheterization and Cardiovascular Interventions 63:2, 141-145
CrossRef309
K. Hekmat, C. Menzel, A. Kroener, R. H. G. Schwinger, S. Kampe, U. M. Fischer, H. J. Geissler, U. Mehlhorn. (2004) The effect of preoperative antiplatelet therapy in coronary artery surgery: blood transfusion requirements for patients on cardiopulmonary bypass. Current Medical Research and Opinion 20:9, 1429-1435
CrossRef310
Charles Chan, Yean-Leng Lim, Teguh Santoso, Damras Tresukosol, Yean-Teng Lim, Shinjo Sonoda, Peter Fitzgerald. (2004) Acute and long-term clinical and angiographic outcome after S-Stent implantation: S-Stent multicenter safety and efficacy trial. Catheterization and Cardiovascular Interventions 62:4, 439-444
CrossRef311
F Philippe, A Sebaoun, C Avierinos, G Julien. (2004) Prescription médicamenteuse au décours d'une angioplastie coronaire : résultats de l'enquête ECART (Évaluation du coronarien après revascularisation). Annales de Cardiologie et d'Angéiologie 53:3, 131-136
CrossRef312
Neal S Kleiman. (2004) Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. Journal of the American College of Cardiology 43:11, 1989-1991
CrossRef313
Marco Zimarino, Raffaele De Caterina. (2004) Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient???s Therapy. Journal of Cardiovascular Pharmacology 43:4, 477-484
CrossRef314
P.A. Ringleb, P.D. Schellinger, C. Schwark. (2004) Clopidogrel in the management of cerebrovascular events. International Journal of Clinical Practice 58:4, 402-410
CrossRef315
Dejan Orlic, Erminio Bonizzoni, Goran Stankovic, Flavio Airoldi, Alaide Chieffo, Nicola Corvaja, Giuseppe Sangiorgi, Massimo Ferraro, Carlo Briguori, Matteo Montorfano, Mauro Carlino, Antonio Colombo. (2004) Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. Journal of the American College of Cardiology 43:7, 1154-1160
CrossRef316
Alan K Jacobson. (2004) Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Practice & Research Clinical Haematology 17:1, 55-64
CrossRef317
Spencer B. King. (2004) From Balloon Angioplasty to Drug-Eluting Stents: Revolution or Evolution?. The American Heart Hospital Journal 2:2, 73-79
CrossRef318
George A. Stouffer, Jana Hirmerova, Stephan Moll, Bryon Rubery, Mark Napoli, E. Magnus Ohman, Ross Simpson. (2004) Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. Catheterization and Cardiovascular Interventions 61:3, 364-367
CrossRef319
Michael H Rosove. (2004) Platelet glycoprotein IIb/IIIa inhibitors. Best Practice & Research Clinical Haematology 17:1, 65-76
CrossRef320
D.J. Betteridge, J. Belch, M.M. Brown, M. Gent, D. Julian, S. Long, S. Morris, J. Pittard, M. Pye. (2004) Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. International Journal of Clinical Practice 58:2, 153-168
CrossRef321
Ganeshkumar Anne, Luis Gruberg. (2004) Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review. Expert Opinion on Pharmacotherapy 5:2, 335-348
CrossRef322
Kastrati, Adnan, Mehilli, Julinda, Schühlen, Helmut, Dirschinger, Josef, Dotzer, Franz, ten Berg, Jurriën M., Neumann, Franz-Josef, Bollwein, Hildegard, Volmer, ChristianGawaz, Meinrad, Berger, Peter B., Schömig, Albert, . (2004) A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. New England Journal of Medicine 350:3, 232-238
Full Text323
Victor L. Serebruany, Alex I. Malinin, Roswith M. Eisert, David C. Sane. (2004) Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. American Journal of Hematology 75:1, 40-47
CrossRef324
Makoto Sekiguchi, Hiroshi Hoshizaki, Hitoshi Adachi, Shigeru Ohshima, Koichi Taniguchi, Masahiko Kurabayashi. (2004) Effects of Antiplatelet Agents on Subacute Thrombosis and Restenosis After Successful Coronary Stenting. Circulation Journal 68:7, 610-614
CrossRef325
David Fiorella, Felipe C. Albuquerque, Patrick Han, Cameron G. McDougall. (2004) Preliminary Experience Using the Neuroform Stent for the Treatment of Cerebral Aneurysms. Neurosurgery 54:1, 6-17
CrossRef326
Yoav Michowitz, Alex Blatt, Aaron Frimmerman, Ariel Finkelstein, Rafi Massachi, Itzhak Herz, Ricardo Krakover, Hylton Miller, Gad Keren, Jacob George. (2004) Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases. Acute Cardiac Care 6:3-4, 160-164
CrossRef327
Arthur Kerner, Luis Gruberg, Michael Kapeliovich, Ehud Grenadier. (2003) Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheterization and Cardiovascular Interventions 60:4, 505-508
CrossRef328
Gregg W. Stone, David A. Cox, Joseph Babb, Dean Nukta, Luc Bilodeau, Louis Cannon, Thomas D. Stuckey, James Hermiller, Eric A. Cohen, Reginald Low, Steven R. Bailey, Alexandra J. Lansky, Richard E. Kuntz. (2003) Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. Journal of the American College of Cardiology 42:11, 2007-2013
CrossRef329
D. R. Holmes. (2003) Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture. Mayo Clinic Proceedings 78:12, 1507-1518
CrossRef330
James S. Forrester. (2003) Toward understanding the evolution of plaque rupture. Journal of the American College of Cardiology 42:9, 1566-1568
CrossRef331
Steven R Steinhubl, Jo E Rodgers. (2003) Clopidogrel’s role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Expert Review of Cardiovascular Therapy 1:4, 507-522
CrossRef332
Ian D. Conde, Neal S. Kleiman. (2003) Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics. Catheterization and Cardiovascular Interventions 60:2, 236-246
CrossRef333
James E Tcheng, Mark E Campbell. (2003) Platelet inhibition strategies in percutaneous coronary intervention. Journal of the American College of Cardiology 42:7, 1196-1198
CrossRef334
Albert W Chan, David J Moliterno, Peter B Berger, Gregg W Stone, Peter M DiBattiste, Steven L Yakubov, Shelly K Sapp, Kathy Wolski, Deepak L Bhatt, Eric J Topol. (2003) Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival. Journal of the American College of Cardiology 42:7, 1188-1195
CrossRef335
Michelle Petri. (2003) Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Current Rheumatology Reports 5:5, 370-373
CrossRef336
Mitchell J Ross, Howard C Herrmann, David J Moliterno, James C Blankenship, Laura Demopoulos, Peter M DiBattiste, Stephen G Ellis, Ziyad Ghazzal, Jack L Martin, Jennifer White, Eric J Topol. (2003) Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology 42:6, 981-988
CrossRef337
Christopher P. Cannon. (2003) Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I. Clinical Cardiology 26:8, 358-364
CrossRef338
Jacqueline Saw, David J. Moliterno. (2003) Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Coronary Artery Disease 14:5, 373-380
CrossRef339
Jacqueline Saw, David Moliterno. (2003) Coronary Artery Disease 14:5, 373-380
CrossRef340
Anna M. Wodlinger, John A. Pieper. (2003) The role of clopidogrel in the management of acute coronary syndromes. Clinical Therapeutics 25:8, 2155-2181
CrossRef341
Stephanie H Wilson, Panayotis Fasseas, James L Orford, Ryan J Lennon, Terese Horlocker, Nina E Charnoff, Steven Melby, Peter B Berger. (2003) Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. Journal of the American College of Cardiology 42:2, 234-240
CrossRef342
T Lefèvre. (2003) Utilisation des « stents actifs » dans les lésions complexes. Annales de Cardiologie et d'Angéiologie 52:3, 176-183
CrossRef343
Christoph W Kopp, Sabine Steiner, Ute Priglinger, Guenter Christ, Peter Probst, Gerald Maurer, Erich Minar, Kurt Huber. (2003) Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting. Blood Coagulation & Fibrinolysis 14:4, 379-386
CrossRef344
Aaron V. Kaplan. (2003) Three-two-one?. Catheterization and Cardiovascular Interventions 59:2, 193-194
CrossRef345
Daniel Soffer, Issam Moussa, Kishore J. Harjai, Judith A. Boura, Simon R. Dixon, Cindy L. Grines, William W. O'Neill, Gary S. Roubin, Jeffrey W. Moses. (2003) Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?. Catheterization and Cardiovascular Interventions 59:1, 21-25
CrossRef346
Peter Berger. (2003) Reply. Journal of the American College of Cardiology 41:8, 1421
CrossRef347
Ranjan Dahiya, James Nance, Dan Johnson, Jon Wilke, Kent Wilson, Robert Hall, Florinda Romero-Vagedes, Christine Wilson, William Jones, Deborah Dye, Julie Dzurick, Janet Ohm, Paula Ericson, Christopher Wendel, Jane Mohler, Prabhdeep S. Sethi, Hoang Thai, Steven Goldman, Edward Dick, Birger Rhenman, Douglass A. Morrison. (2003) Critical Pathway for Cardiac Rehabilitation After Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:1, 7-14
CrossRef348
Kyung W. Park. (2003) Preoperative Cardiology Consultation. Anesthesiology 98:3, 754-762
CrossRef349
Richard C. Becker. (2003) Acute myocardial infarction: Antithrombotic therapy. Current Treatment Options in Cardiovascular Medicine 5:1, 3-11
CrossRef350
Thaddeus R Tolleson, J.Conor O’Shea, John A Bittl, William B Hillegass, Kathryn A Williams, Glenn Levine, Robert A Harrington, James E Tcheng. (2003) Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. Journal of the American College of Cardiology 41:3, 386-393
CrossRef351
Shamir R Mehta, Salim Yusuf. (2003) Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Journal of the American College of Cardiology 41:4, S79-S88
CrossRef352
Richard Shlansky-Goldberg. (2003) Oral Antiplatelet Therapy for Peripheral Vascular Disease. Journal of Vascular and Interventional Radiology 14:2, P279-P283
CrossRef353
Can M Nguyen, Robert A Harrington. (2003) Glycoprotein IIb/IIIa Receptor Antagonists. American Journal of Cardiovascular Drugs 3:6, 423-436
CrossRef354
Ender Semiz, Cengiz Ermis, Selim Yalçinkaya, Oktay Sancaktar, Necmi Deger. (2003) Comparison of Initial Efficacy and Long-term Follow-up of Heparin-coated Jostent With Conventional NIR Stent. Japanese Heart Journal 44:6, 889-898
CrossRef355
Archibald McNicol, Sara J. Israels. (2003) Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences 93:4, 381-396
CrossRef356
Marc G Van der Planken, Marc J Claeys, Francine J Vertessen, Dagmara Dilling, Johan M Bosmans, Zwi N Berneman, Jan J Michiels, Christian Vrints. (2003) Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thrombosis Research 111:3, 159-164
CrossRef357
Jose A. Silva, Christopher J. White, Stephen R. Ramee, Tyrone J. Collins, J. Stephen Jenkins, Kalon Ho, Donald S. Baim, Joseph P. Carrozza, Stephane Rinfret, Cindy M. Setum, Jeffrey J. Popma, Richard E. Kuntz. (2003) Treatment of coronary stent thrombosis with rheolytic thrombectomy: Results from a multicenter experience. Catheterization and Cardiovascular Interventions 58:1, 11-17
CrossRef358
Sabine Steiner, Ramazanali Ahmadi, Andrea Willfort, Wilfried Lang, Kurt Huber, Erich Minar, Christoph W. Kopp. (2003) Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting. Thrombosis Research 109:1, 23-29
CrossRef359
P. C. A. Kam, C. M. Nethery. (2003) The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58:1, 28-35
CrossRef360
Holger Eggebrecht, Michael Haude, Uta Woertgen, Axel Schmermund, Clemens von Birgelen, Christoph Naber, Dietrich Baumgart, Christoph Kaiser, Olaf Oldenburg, Thomas Bartel, Knut Kroeger, Raimund Erbel. (2002) Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1,317 consecutive patients. Catheterization and Cardiovascular Interventions 57:4, 486-495
CrossRef361
Patricia A. Howard, Edward F. Ellerbeck, Kimberly K. Engelman, Kelly L. Patterson. (2002) The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiology and Drug Safety 11:7, 569-576
CrossRef362
W BRINKMAN, T TERRAMANI, S NAJIBI, E CHAIKOF. (2002) Platelets: Is aspirin sufficient or must we know how to pronounce abciximab?. Seminars in Vascular Surgery 15:4, 245-255
CrossRef363
Murad Alam, Leonard H. Goldberg. (2002) Serious Adverse Vascular Events Associated With Perioperative Interruption of Antiplatelet and Anticoagulant Therapy. Dermatologic Surgery 28:11, 992-998
CrossRef364
James L Orford, Ryan Lennon, Steven Melby, Panayotis Fasseas, Malcolm R Bell, Charanjit S Rihal, David R Holmes, Peter B Berger. (2002) Frequency and correlates of coronary stent thrombosis in the modern era. Journal of the American College of Cardiology 40:9, 1567-1572
CrossRef365
Jose M. Wiley, Christopher J. White, Barry F. Uretsky. (2002) Noncoronary complications of coronary intervention. Catheterization and Cardiovascular Interventions 57:2, 257-265
CrossRef366
Samuel C. Yoon, Warren K. Laskey, Assadour Assadourian, Debra Kelly, Joel Gellman, William Herzog, J. Lawrence Stafford. (2002) Assessment of contemporary stent deployment using intravascular ultrasound. Catheterization and Cardiovascular Interventions 57:2, 150-154
CrossRef367
St
phane Rinfret, Donald E. Cutlip, Peter T. Katsiyiannis, Kalon K.L. Ho, David J. Cohen, Joseph P. Carrozza, Roger J. Laham. (2002) Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosis. Catheterization and Cardiovascular Interventions 57:1, 24-30
CrossRef368
Gary M. Ansel, Charles F. Botti, Barry S. George, Brian T. Kazienko, . (2002) Clinical results for the training-phase roll-in patients in the intracoil femoralpopliteal stent trial. Catheterization and Cardiovascular Interventions 56:4, 443-449
CrossRef369
Sridhar Kamath, Andrew D Blann, Bernard S.P Chin, Gregory Y.H Lip. (2002) A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. Journal of the American College of Cardiology 40:3, 484-490
CrossRef370
David E. Kandzari, James E. Tcheng, James P. Zidar. (2002) Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention. Catheterization and Cardiovascular Interventions 56:4, 562-576
CrossRef371
(2002) Periodontal Management of Patients With Cardiovascular Diseases. Journal of Periodontology 73:8, 954-968
CrossRef372
Mitchell J. Silver, Gary M. Ansel. (2002) Femoropopliteal occlusive disease: Diagnosis, indications for treatment, and results of interventional therapy. Catheterization and Cardiovascular Interventions 56:4, 555-561
CrossRef373
MARTIN UNVERDORBEN, NIKOLAUS REIFART, RALF DEGENHARDT, ROLAND BACH, BENNO HENNEN, JOHANNES DAHM, DETLEF MATHEY, DIETRICH PFEIFFER, HEINER K. BERTHOLD, CHRISTIAN VALLBRACHT. (2002) Restenosis Rates with Flexible GFX Stents (REFLEX): Clinical and angiographic Results. Journal of Interventional Cardiology 15:4, 269-275
CrossRef374
L. Adams, G. P. Jeffrey, B. Deboer, G. Garas. (2002) Ticlopidine-associated cholestatic hepatitis. Internal Medicine Journal 32:7, 359-360
CrossRef375
Richard H Hongo, Jill Ley, Stuart E Dick, Rupsa R Yee. (2002) The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting. Journal of the American College of Cardiology 40:2, 231-237
CrossRef376
H
CrossRef377
DEBORAH SHATIN, STEPHANIE D. SCHECH, ALLEN BRINKER. (2002) Ambulatory Use of Ticlopidine and Clopidogrel in Association with Percutaneous Coronary Revascularization Procedures in a National Managed Care Organization. Journal of Interventional Cardiology 15:3, 181-186
CrossRef378
M. J. Claeys, M. G. Van der Planken, J. J. Michiels, F. Vertessen, D. Dilling, J. M. Bosmans, C. J. Vrints. (2002) Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagulation & Fibrinolysis 13:4, 283-288
CrossRef379
Seung H. Lee, Istvan Szinai, Kenneth Carpenter, Ramaz Katsarava, Giuli Jokhadze, Chih-Chang Chu, Yanming Huang, Eric Verbeken, Orville Bramwell, Ivan De Scheerder, Mun K. Hong. (2002) In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coronary Artery Disease 13:4, 237-241
CrossRef380
Dale T. Ashby, George Dangas, Roxana Mehran, Martin B. Leon. (2002) Coronary artery stenting. Catheterization and Cardiovascular Interventions 56:1, 83-102
CrossRef381
J
CrossRef382
R SHLANSKYGOLDBERG. (2002) Platelet Aggregation Inhibitors for Use in Peripheral Vascular Interventions: What Can We Learn from the Experience in the Coronary Arteries?. Journal of Vascular and Interventional Radiology 13:3, 229-246
CrossRef383
John M. Lasala. (2002) Stent thrombosis: It's never too late!. Catheterization and Cardiovascular Interventions 55:2, 148-149
CrossRef384
Fenwei Wang, George A. Stouffer, Sergio Waxman, Barry F. Uretsky. (2002) Late coronary stent thrombosis: Early vs. late stent thrombosis in the stent era. Catheterization and Cardiovascular Interventions 55:2, 142-147
CrossRef385
DIETER F. LUBBE, PETER B. BERGER. (2002) The Thienopyridines. Journal of Interventional Cardiology 15:1, 85-93
CrossRef386
Antonio L. Bartorelli, Daniela Trabattoni, Piero Montorsi, Franco Fabbiocchi, Stefano Galli, Paolo Ravagnani, Luca Grancini, Sergio Cozzi, Alessandro Loaldi. (2002) Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent?: The Antares study. Catheterization and Cardiovascular Interventions 55:2, 150-156
CrossRef387
Deepak L Bhatt, Michel E Bertrand, Peter B Berger, Philippe L L’Allier, Issam Moussa, Jeffrey W Moses, George Dangas, Megumi Taniuchi, John M Lasala, David R Holmes, Stephen G Ellis, Eric J Topol. (2002) Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology 39:1, 9-14
CrossRef388
Ryosai Nakamura, Takuroh Imamura, Hisamitsu Onitsuka, Kazuya Mishima, Tetsunori Ishikawa, Toshiro Nagoshi, Yoshitake Fujiura, Haruhiko Date, Masakazu Maeno, Takeshi Matsuo, Yasushi Koiwaya, Tanenao Eto. (2002) Interstitial Pneumonia Induced by Ticlopidine. Circulation Journal 66:8, 773-773
CrossRef389
Joseph K. Choo, John J. Young, Dean J. Kereiakes. (2002) A Guide to Drug Use During Percutaneous Coronary Intervention. Drugs 62:18, 2589-2601
CrossRef390
A. James O'Malley, Sharon-lise T. Normand, Richard E. Kuntz. (2002) Application of models for multivariate mixed outcomes to medical device trials: coronary artery stenting. Statistics in Medicine 22:2, 313-336
CrossRef391
A. Michael Lincoff. (2001) Anticoagulant and antiplatelet drugs. Catheterization and Cardiovascular Interventions 54:4, 514-520
CrossRef392
Andrew Farb, Allen P. Burke, Renu Virmani. (2001) Evaluation of Intravascular Stents. Pathology Case Reviews 6:6, 253-264
CrossRef393
Wayne B. Batchelor, Kenneth W. Mahaffey, Peter B. Berger, Ezra Deutsch, Susan Meier, Vic Hasselblad, Edward T. Fry, Paul S. Teirstein, Allan M. Ross, Cynthia A. Binanay, James P. Zidar. (2001) A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. Journal of the American College of Cardiology 38:6, E1608-E1613
CrossRef394
Samer M Garas, Philip Huber, Neal A Scott. (2001) Overview of therapies for prevention of restenosis after coronary interventions. Pharmacology & Therapeutics 92:2-3, 165-178
CrossRef395
Benilde Cosmi, Andrea Rubboli, Cristina C Castelvetri, Milena Milandri, Benilde Cosmi. 2001. Ticlopidine versus oral anticoagulation for coronary stenting. .
CrossRef396
Scott A. Harding, Charles J. McKenna, Andrew D. Flapan, Nicholas A. Boon. (2001) Long-term clinical safety and efficacy of NIROYAL vs. NIR intracoronary stent. Catheterization and Cardiovascular Interventions 54:2, 141-145
CrossRef397
Scott A. Harding, Darren L. Walters, Igor F. Palacios, Stephen N. Oesterle. (2001) Adjunctive pharmacotherapy for coronary stenting. Current Opinion in Cardiology 16:5, 293-299
CrossRef398
Gary Redekop, Thomas Marotta, Alain Weill. (2001) Treatment of traumatic aneurysms and arteriovenous fistulas of the skull base by using endovascular stents. Journal of Neurosurgery 95:3, 412-419
CrossRef399
Jeffrey T. W. Pang, Stephen Fort, Anthony Delia Siega, Eric A. Cohen. (2001) Emergency Coronary Artery Bypass Surgery in the Era of Glycoprotein IIb/IIIa Receptor Antagonist Use. Journal of Cardiac Surgery 17:5, 425-431
CrossRef400
Eric Graaff, Steven R. Steinhubl. (2001) Complications of oral antiplatelet medications. Current Cardiology Reports 3:5, 371-379
CrossRef401
Takamichi Miyamoto, Akihiro Niwa, Toshio Sinoda. (2001) State of Percutaneous Transluminal Coronary Artery Angioplasty and Effectiveness of Low-Density Lipoprotein Apheresis. Therapeutic Apheresis and Dialysis 5:4, 226-231
CrossRef402
Sidney C. Smith, James T. Dove, Alice K. Jacobs, J. Ward Kennedy, Dean Kereiakes, Morton J. Kern, Richard E. Kuntz, Jeffery J. Popma, Hartzell V. Schaff, David O. Williams, Raymond J. Gibbons, Joseph P. Alpert, Kim A. Eagle, David P. Faxon, Valentin Fuster, Timothy J. Gardner, Gabriel Gregoratos, Richard O. Russell, Sidney C. Smith. (2001) ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). Journal of the American College of Cardiology 37:8, 2239
CrossRef403
GERD HAUSDORF. (2001) Vascular Access, Vessel Thrombosis, Vessel Reconstruction. Journal of Interventional Cardiology 14:3, 385-396
CrossRef404
Vijay G. Kalaria, Frederick S. Ling. (2001) Late stent thrombosis without antecedent brachytherapy: Confirmation and treatment with rheolytic thrombectomy. Catheterization and Cardiovascular Interventions 53:2, 243-247
CrossRef405
Helmut Schühlen, Adnan Kastrati, Jürgen Pache, Josef Dirschinger, Albert Schömig. (2001) Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. Journal of the American College of Cardiology 37:8, 2066-2073
CrossRef406
Louis I. Heller, Kathie C. Shemwell, Karen Hug. (2001) Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheterization and Cardiovascular Interventions 53:1, 23-28
CrossRef407
Benilde Cosmi, Eleonora Conti, Sergio Coccheri, Benilde Cosmi. 2001. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. .
CrossRef408
J CALVIN, L KLEIN. (2001) THE USE OF ANTIPLATELET AGENTS IN ACUTE CARDIAC CARE. Critical Care Clinics 17:2, 365-377
CrossRef409
Erdal Cavusoglu, Samin K. Sharma, William Frishman. (2001) Unstable Angina Pectoris and Non-Q-Wave Myocardial Infarction. Heart Disease116-130
CrossRef410
Barbara S. Wiggins, Ann K. Wittkowsky, Jean M. Nappi. (2001) Clinical Use of New Antithrombotic Therapies for Medical Management of Acute Coronary Syndromes. Pharmacotherapy 21:3, 320-337
CrossRef411
Manish S Chauhan, Richard E Kuntz, Kalon K.L Ho, David J Cohen, Jeffrey J Popma, Joseph P Carrozza, Donald S Baim, Donald E Cutlip. (2001) Coronary artery stenting in the aged. Journal of the American College of Cardiology 37:3, 856-862
CrossRef412
Richard Heuser, Alejandro Lopez, Richard Kuntz, Lawrence Reduto, Rodney Badger, Patrick Coleman, Patrick Whitlow, L. A. Iannone, Robert Safian, Alan Yeung, Jeffrey Moses, . (2001) SMART: The microstent's ability to limit restenosis trial. Catheterization and Cardiovascular Interventions 52:3, 269-277
CrossRef413
&NA;. (2001) Adjunctive therapy with antiplatelet agents prevents stent thrombosis. Drugs & Therapy Perspectives 17:4, 8-11
CrossRef414
Kean-Wah Lau, Zee-Pin Ding, Veronica Kwok, Ulrich Sigwart. (2001) Early and mid-term angiographic and clinical results after intracoronary duet stent placement. Catheterization and Cardiovascular Interventions 52:2, 173-176
CrossRef415
Helfried Metzler. (2001) Preoperative interventional cardiology in noncardiac surgery: benefit or risk?. Current Opinion in Anaesthesiology 14:1, 1-2
CrossRef416
Antonis S. Manolis. (2001) Reduced incidence of clinical restenosis with newer generation stents, stent oversizing, and high-pressure deployment: Single-operator experience. Clinical Cardiology 24:2, 119-126
CrossRef417
Joel S. Bennett. (2001) N
OVEL PLATELET INHIBITORS . Annual Review of Medicine 52:1, 161-184
CrossRef418
MARK R. ADAMS, GAVIN J. BLAKE, SCOTT KINLAY, CAMPBELL ROGERS. (2001) Rheolytic Thrombectomy for In-Stent Thrombosis: Creating a Diagnostic Window. Journal of Interventional Cardiology 14:1, 27-31
CrossRef419
Leon, Martin B., Teirstein, Paul S., Moses, Jeffrey W., Tripuraneni, Prabhakar, Lansky, Alexandra J., Jani, Shirish, Wong, S. Chiu, Fish, David, Ellis, Stephen, Holmes, David R., Kerieakes, Dean, Kuntz, Richard E., . (2001) Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal of Medicine 344:4, 250-256
Full Text420
Kyung W. Park. (2001) Critical Review of the ACC/AHA Algorithm for Stratifying Cardiac Patients for Noncardiac Surgery. International Anesthesiology Clinics 39:4, 81-92
CrossRef421
Charles R. Cannan. (2001) Antithrombotic therapy in cardiac stent patients. Current Cardiology Reports 3:1, 78-84
CrossRef422
DJA Price, PG Campbell, AGC Sutton, ED. (2001) Selective use of abciximab in coronary stenting: overall outcomes can still be equivalent to those in the EPISTENT treatment group. Acute Cardiac Care 4:1, 15-20
CrossRef423
Tilo Grosser. (2001) Physiology and Pharmacology of Oral Antiplatelet Medications. Journal of Vascular and Interventional Radiology 12:1, P29-P31
CrossRef424
M CEJNA, S THURNHER, H ILLIASCH, W HORVATH, P WALDENBERGER, K HORNIK, J LAMMER. (2001) PTA versus Palmaz Stent Placement in Femoropopliteal Artery Obstructions: A Multicenter Prospective Randomized Study. Journal of Vascular and Interventional Radiology 12:1, 23-31
CrossRef425
Ali Moustapha, H. Vernon Anderson. (2000) Revascularization interventions for ischemic heart disease. Current Opinion in Cardiology 15:6, 463-471
CrossRef426
Ameet Bakhai, Rodney H Stables, Sanjay Prasad, Ulrich Sigwart. (2000) Trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multivessel coronary artery disease. Current Opinion in Cardiology 15:6, 388-394
CrossRef427
Fernando Alfonso, Carlos Hernández, Marı́a José Pérez-Vizcayno, Rosana Hernández, Antonio Fernández-Ortı́z, Javier Escaned, Camino Bañuelos, Manel Sabaté, Marcelo Sanmartı́n, Cristina Fernández, Carlos Macaya. (2000) Fate of stent-related side branches after coronary intervention in patients with in-stent restenosis. Journal of the American College of Cardiology 36:5, 1549-1556
CrossRef428
Luis Gruberg, Ron Waksman, Lowell F Satler, Augusto D Pichard, Kenneth M Kent. (2000) Novel approaches for the prevention of restenosis. Expert Opinion on Investigational Drugs 9:11, 2555-2578
CrossRef429
S. B. King III. (2000) Optimizing Antiplatelet Therapy in Coronary Interventions. Clinical Cardiology 23:S6, 8-13
CrossRef430
G. Montalescot. (2000) Value of Antiplatelet Therapy in Preventing Thrombotic Events in Generalized Vascular Disease. Clinical Cardiology 23:S6, 18-22
CrossRef431
Jeffrey D. Kerby, Addison K. May, Camilo R. Gomez, Loring W. Rue. (2000) Treatment of Bilateral Blunt Carotid Injury Using Percutaneous Angioplasty and Stenting: Case Report and Review of the Literature. The Journal of Trauma: Injury, Infection, and Critical Care 49:4, 784-787
CrossRef432
Sunil V. Rao, James G. Jollis. (2000) Mayo Clinic Proceedings. Mayo Clinic Proceedings 75:10, 991-993
CrossRef433
Khatereh Moshfegh, Maurice Redondo, Friedgard Julmy, Walter A Wuillemin, Mathias U Gebauer, André Haeberli, Beat J Meyer. (2000) Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Journal of the American College of Cardiology 36:3, 699-705
CrossRef434
Mark I. Furman, Andrew L. Frelinger, Alan D. Michelson. (2000) Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents. Current Cardiology Reports 2:5, 386-394
CrossRef435
KENICHI FUJISE, PETER A. YHIP, H. VERNON ANDERSON, GEORGE SCHROTH, OSCAR ROSALES, RICHARD W. SMALLING. (2000) Balloon to Artery Ratio, Not Inflation Pressure, Correlates with Adequate Stent Deployment: Size Is More Important than Pressure. Journal of Interventional Cardiology 13:4, 223-229
CrossRef436
Steven R Steinhubl. (2000) Antiplatelet agents in cardiology: the choice of therapy. The Annals of Thoracic Surgery 70:2, S3-S8
CrossRef437
Mohammad M. Alsolaiman, Khai Chang, Heider Arjomand, Rajen Oza, Gary Costacurta. (2000) Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: Treatment with coronary angioplasty. Catheterization and Cardiovascular Interventions 50:4, 468-472
CrossRef438
F López-Jiménez. (2000) Update in Internal Medicine. Archives of Medical Research 31:4, 329-352
CrossRef439
Daniel M. Kolansky, Bruce D. Klugherz, Sean C. Curran, Howard C. Herrmann, Kathleen Magness, Robert L. Wilensky, John W. Hirshfeld. (2000) Combination therapy with clopidogrel and aspirin after coronary stenting. Catheterization and Cardiovascular Interventions 50:3, 276-279
CrossRef440
Harold L. Dauerman, Ross Prpic, Costa Andreou, Mary A. Vu, Jeffrey J. Popma. (2000) Angiographic and clinical outcomes after rescue coronary stenting. Catheterization and Cardiovascular Interventions 50:3, 269-275
CrossRef441
Thomas J. Linnemeier. (2000) On the resilience of coronary stents: Are they timeless or do they corrode?. Catheterization and Cardiovascular Interventions 50:2, 175-176
CrossRef442
Bradford B. Worrall, Karen C. Johnston. (2000) Antiplatelet agents, carotid endarterectomy, and perioperative complications. Neurosurgical FOCUS 8:5, 1-4
CrossRef443
O MEISSNER, R PRETTNER, W KELLNER, U SZEIMIES, B STECKMEIER, F SPENGEL, G KUEFFER. (2000) Endoluminal Repair of Peripheral Arterial Aneurysms: 4-Year Experience with the Cragg EndoPro System I. Journal of Vascular and Interventional Radiology 11:5, 593-600
CrossRef444
Jae Wook Ko, Zeruesenay Desta, Nadia V Soukhova, Timothy Tracy, David A Flockhart. (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. British Journal of Clinical Pharmacology 49:4, 343-351
CrossRef445
Grzegorz L Kałuza, Jane Joseph, Joseph R Lee, Michael E Raizner, Albert E Raizner. (2000) Catastrophic outcomes of noncardiac surgery soon after coronary stenting. Journal of the American College of Cardiology 35:5, 1288-1294
CrossRef446
A.Michael Lincoff, Robert M Califf, Eric J Topol. (2000) Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Journal of the American College of Cardiology 35:5, 1103-1115
CrossRef447
Ran Kornowski, Balram Bhargava, D.M.Shmuel Fuchs, Alexandra J Lansky, Lowell F Satler, Augusto D Pichard, Mun K Hong, Kenneth M Kent, Roxana Mehran, Gregg W Stone, Martin B Leon. (2000) Procedural results and late clinical outcomes after percutaneous interventions using long (≥25 mm) versus short (<20 mm) stents. Journal of the American College of Cardiology 35:3, 612-618
CrossRef448
James C. Blankenship, Gregory J. Mishkel, Charles E. Chambers, John McB. Hodgson, David R. Holmes, William Sheldon, Marc J. Schweiger, Michael J. Cowley, Jeffrey J. Popma, . (2000) Ad hoc coronary intervention. Catheterization and Cardiovascular Interventions 49:2, 130-134
CrossRef449
Krishna J. Rocha-Singh, Karen J. McShane, Robert Ligon, Chung-Hsien Sung. (2000) One-year clinical outcomes and relative costs of primary infarct artery stenting versus angioplasty following systemic thrombolysis for acute myocardial infarction. Catheterization and Cardiovascular Interventions 49:2, 135-141
CrossRef450
Yeghiazarians, Yerem, Braunstein, Joel B., Askari, Arman, Stone, Peter H., . (2000) Unstable Angina Pectoris. New England Journal of Medicine 342:2, 101-114
Full Text451
Gail Richardson, Nicholas P Curzen, Mela. (2000) Failure to monitor ticlopidine: the case for clopidogrel. Acute Cardiac Care 3:1, 29-33
CrossRef452
Deepak L. Bhatt, Eric J. Topol. (2000) ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE. Medical Clinics of North America 84:1, 163-179
CrossRef453
JL Boland, HAM Corbeij, W Van Der Giessen, R Seabra-Gomes, H Suryapranata, W Wijns, C Hanet, MJ Suttorp, C Buller, JJRM Bonnier, A Colombo, C Van Birgelen, M Pieper, JA Mangioni, H Londero, RG Carere, CW Hamm, R Bonan, A Bartorelli, ZS Kyriakides. (2000) Multicenter evaluation of the phosphorylcholinecoated biodivYsio stent in short de novo coronary lesions: The SOPHOS study. Acute Cardiac Care 3:4, 215-225
CrossRef454
Eric Van De Graaff, Steven R Steinhubl. (2000) Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Annals of Medicine 32:8, 561-571
CrossRef455
Rankin, James M., Spinelli, John J., Carere, Ronald G., Ricci, Donald R., Penn, Ian M., Hilton, J. David, Henderson, Mark A., Hayden, Robert I., Buller, Christopher E., . (1999) Improved Clinical Outcome after Widespread Use of Coronary-Artery Stenting in Canada. New England Journal of Medicine 341:26, 1957-1965
Full Text456
(1999) Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease. New England Journal of Medicine 341:24, 1853-1855
Full Text457
Peter B Berger, Malcolm R Bell, Charanjit S Rihal, Henry Ting, Gregory Barsness, Kirk Garratt, Victoria Bellot, Verghese Mathew, Steve Melby, LaVon Hammes, Diane Grill, David R Holmes. (1999) Clopidogrel versus ticlopidine after intracoronary stent placement. Journal of the American College of Cardiology 34:7, 1891-1894
CrossRef458
Gregory J Mishkel, Frank V Aguirre, Robert W Ligon, Krishna J Rocha-Singh, Charles L Lucore. (1999) Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. Journal of the American College of Cardiology 34:7, 1884-1890
CrossRef459
Eric J Topol, Daniel B Mark, A Michael Lincoff, Eric Cohen, Jeffrey Burton, Neal Kleiman, David Talley, Shelly Sapp, Joan Booth, Catherine F Cabot, Keaven M Anderson, Robert M Califf. (1999) Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. The Lancet 354:9195, 2019-2024
CrossRef460
Stefano De Servi, Giuseppe Mariani, Irene Bossi, Catherine Klersy, Paolo Rubartelli, Luigi Niccoli, Alessandra Repetto, Luigi Giommi, Giovanni Baduini, Aleardo Maresta, Sergio Repetto. (1999) One-year outcome in multivessel coronary disease patients undergoing coronary stenting. Catheterization and Cardiovascular Interventions 48:4, 343-349
CrossRef461
Gérard Helft, Paolo Bartolomeo, Azfar G Zaman, Stephen G Worthley, Sylvie Chokron, Claude Le Pailleur, Farzyn Beygui, Claude Le Feuvre, Jean-Philippe Metzger, André Vacheron, Michel M Samama. (1999) The Heparin Management Test. Thrombosis Research 96:6, 481-485
CrossRef462
James R. Wilentz, Gregory Mishkel, Denise McDermott, Kumar Ravi, John T. Fox, Carl D. Reimers, Shannon Maydick. (1999) Outpatient coronary stenting: Femoral approach with vascular sealing. Herz 24:8, 624-633
CrossRef463
Lloyd W Klein, James E Calvin. (1999) Use of clopidrogel in coronary stenting: what was the question?. Journal of the American College of Cardiology 34:7, 1895-1898
CrossRef464
JOSEPH B. MUHLESTEIN, CHLOE ALLEN MAYCOCK. (1999) Routine Stenting or Provisional Stenting: Which Is Better? A Look At Presently Existing Data. Journal of Interventional Cardiology 12:5, 389-394
CrossRef465
Eric Eeckhout, Michel Grob
CrossRef466
Donald E Cutlip, Martin B Leon, Kalon K.L Ho, Paul C Gordon, Alessandro Giambartolomei, Daniel J Diver, David M Lasorda, David O Williams, Michelle M Fitzpatrick, April Desjardin, Jeffrey J Popma, Richard E Kuntz, Donald S Baim. (1999) Acute and nine-month clinical outcomes after “suboptimal” coronary stenting. Journal of the American College of Cardiology 34:3, 698-706
CrossRef467
Jeffrey J. Popma, Robert N. Piana, Ross Prpic. (1999) Clinical trials in interventional cardiology. Current Opinion in Cardiology 14:5, 412
CrossRef468
Rajiv Jauhar, Geoffrey Bergman, Sara Savino, Ezra Deutsch, Alexander Shaknovich, Manish Parikh, Timothy A Sanborn. (1999) Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. The American Journal of Cardiology 84:6, 726-728
CrossRef469
Peter B. Berger. (1999) The thienopyridines in coronary artery disease. Current Cardiology Reports 1:3, 192-198
CrossRef470
Goetz M. Richter, Julio C. Palmaz, Gerd Noeldge, Fermin Tio. (1999) Relationship between Blood Flow, Thrombus, and Neointima in Stents
. Journal of Vascular and Interventional Radiology 10:5, 598-604
CrossRef471
(1999) Antithrombotic Therapy after Coronary-Artery Stenting. New England Journal of Medicine 340:17, 1365-1368
Full Text472
J. DAVID TALLEY. (1999) Interventional Management of Acute Coronary Syndromes. Journal of Interventional Cardiology 12:2, 117-132
CrossRef473
Shamir R. Mehta. (1999) Coronary stenting reduced the rate of restenosis in patients with a first or subsequent restenosis. Evidence-based Cardiovascular Medicine 3:1, 13
CrossRef474
Topol, Eric J., . (1998) Coronary-Artery Stents — Gauging, Gorging, and Gouging. New England Journal of Medicine 339:23, 1702-1704
Full Text
- Letters
